

ALERE INC.  
Form 10-Q  
August 08, 2013  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended June 30, 2013

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

COMMISSION FILE NUMBER 001-16789

**ALERE INC.**

Edgar Filing: ALERE INC. - Form 10-Q

(Exact name of registrant as specified in its charter)

**DELAWARE**  
(State or other jurisdiction of  
incorporation or organization)

**04-3565120**  
(I.R.S. Employer  
Identification No.)

**51 SAWYER ROAD, SUITE 200**

**WALTHAM, MASSACHUSETTS 02453**

(Address of principal executive offices)(Zip code)

**(781) 647-3900**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. **Yes**  **No**

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). **Yes**  **No**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company)

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). **Yes**  **No**

The number of shares outstanding of the registrant's common stock, par value of \$0.001 per share, as of August 5, 2013 was 81,753,992.

**Table of Contents**

**ALERE INC.**

**REPORT ON FORM 10-Q**

**For the Quarterly Period Ended June 30, 2013**

*This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can identify these statements by forward-looking words such as may, could, should, would, intend, will, expect, anticipate, believe, estimate, continue or similar words. A number of important factors could cause actual results of Alere Inc. and its subsidiaries to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the risk factors detailed in Part I, Item 1A, Risk Factors, of our Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2012 and other risk factors identified herein or from time to time in our periodic filings with the Securities and Exchange Commission. Readers should carefully review these risk factors, and should not place undue reliance on our forward-looking statements. These forward-looking statements are based on information, plans and estimates at the date of this report. We undertake no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.*

*Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to we, us and our refer to Alere Inc. and its subsidiaries.*

**TABLE OF CONTENTS**

	<b>PAGE</b>
<b><u>PART I. FINANCIAL INFORMATION</u></b>	3
<u>Item 1. Financial Statements</u>	3
<u>a) Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2013 and 2012</u>	3
<u>b) Consolidated Statements of Comprehensive Income (Loss) for the Three and Six Months Ended June 30, 2013 and 2012</u>	4
<u>c) Consolidated Balance Sheets as of June 30, 2013 and December 31, 2012</u>	5
<u>d) Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2013 and 2012</u>	6
<u>e) Notes to Consolidated Financial Statements</u>	7
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	38
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	49
<u>Item 4. Controls and Procedures</u>	49
<b><u>PART II. OTHER INFORMATION</u></b>	49
<u>Item 6. Exhibits</u>	49
<b><u>SIGNATURES</u></b>	51

**Table of Contents****PART I FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS****ALERE INC. AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF OPERATIONS**

(unaudited)

(in thousands, except per share amounts)

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2013</b>	<b>2012</b>	<b>2013</b>	<b>2012</b>
Net product sales	\$ 521,562	\$ 463,425	\$ 1,029,838	\$ 939,212
Services revenue	237,558	233,855	464,467	426,289
Net product sales and services revenue	759,120	697,280	1,494,305	1,365,501
License and royalty revenue	4,865	3,237	8,929	6,145
<b>Net revenue</b>	<b>763,985</b>	<b>700,517</b>	<b>1,503,234</b>	<b>1,371,646</b>
Cost of net product sales	253,189	222,498	506,267	448,052
Cost of services revenue	124,810	120,559	244,968	211,419
Cost of net product sales and services revenue	377,999	343,057	751,235	659,471
Cost of license and royalty revenue	1,499	1,852	3,255	3,496
<b>Cost of net revenue</b>	<b>379,498</b>	<b>344,909</b>	<b>754,490</b>	<b>662,967</b>
<b>Gross profit</b>	<b>384,487</b>	<b>355,608</b>	<b>748,744</b>	<b>708,679</b>
Operating expenses:				
Research and development	40,500	40,447	81,954	79,447
Sales and marketing	159,422	159,322	315,878	317,900
General and administrative	140,161	121,485	276,019	241,920
Total operating expenses	340,083	321,254	673,851	639,267
<b>Operating income</b>	<b>44,404</b>	<b>34,354</b>	<b>74,893</b>	<b>69,412</b>
Interest expense, including amortization of original issue discounts and deferred financing costs	(92,453)	(55,531)	(149,852)	(106,258)
Other income (expense), net	1,063	3,811	593	15,642
<b>Loss before provision (benefit) for income taxes</b>	<b>(46,986)</b>	<b>(17,366)</b>	<b>(74,366)</b>	<b>(21,204)</b>
Provision (benefit) for income taxes	17,867	(489)	(19,004)	(1,944)
<b>Loss before equity earnings of unconsolidated entities, net of tax</b>	<b>(64,853)</b>	<b>(16,877)</b>	<b>(55,362)</b>	<b>(19,260)</b>
Equity earnings of unconsolidated entities, net of tax	4,551	3,998	7,485	7,410
<b>Net loss</b>	<b>(60,302)</b>	<b>(12,879)</b>	<b>(47,877)</b>	<b>(11,850)</b>

Edgar Filing: ALERE INC. - Form 10-Q

Less: Net income (loss) attributable to non-controlling interests	267	36	242	(149)
<b>Net loss attributable to Alere Inc. and Subsidiaries</b>	(60,569)	(12,915)	(48,119)	(11,701)
Preferred stock dividends	(5,309)	(5,279)	(10,559)	(10,588)
<b>Net loss available to common stockholders</b>	\$ (65,878)	\$ (18,194)	\$ (58,678)	\$ (22,289)
<b>Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries:</b>	\$ (0.81)	\$ (0.23)	\$ (0.72)	\$ (0.28)
<b>Weighted-average shares-basic and diluted</b>	81,311	80,375	81,255	80,307

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents****ALERE INC. AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS**

(unaudited)

(in thousands)

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2013</b>	<b>2012</b>	<b>2013</b>	<b>2012</b>
Net loss	\$ (60,302)	\$ (12,879)	\$ (47,877)	\$ (11,850)
Other comprehensive income (loss), before tax:				
Changes in cumulative translation adjustment	(34,428)	(36,777)	(109,783)	(838)
Unrealized gains on available for sale securities		359		790
Unrealized gains (losses) on hedging instruments		(652)	11	455
Minimum pension liability adjustment	99	4	704	(120)
Other comprehensive income (loss), before tax	(34,329)	(37,066)	(109,068)	287
Income tax provision (benefit) related to items of other comprehensive income				
Other comprehensive income (loss), net of tax	(34,329)	(37,066)	(109,068)	287
Comprehensive loss	(94,631)	(49,945)	(156,945)	(11,563)
Less: Comprehensive income (loss) attributable to non-controlling interests	267	36	242	(149)
Comprehensive loss attributable to Alere Inc. and Subsidiaries	\$ (94,898)	\$ (49,981)	\$ (157,187)	\$ (11,414)

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents****ALERE INC. AND SUBSIDIARIES****CONSOLIDATED BALANCE SHEETS**

(unaudited)

(in thousands, except par value)

	June 30, 2013	December 31, 2012
<b>ASSETS</b>		
<b>Current assets:</b>		
Cash and cash equivalents	\$ 320,547	\$ 328,346
Restricted cash	9,919	3,076
Marketable securities	889	904
Accounts receivable, net of allowances of \$57,939 and \$36,395 at June 30, 2013 and December 31, 2012, respectively	553,760	524,332
Inventories, net	356,753	337,121
Deferred tax assets	60,849	67,722
Prepaid expenses and other current assets	106,360	145,236
<b>Total current assets</b>	<b>1,409,077</b>	<b>1,406,737</b>
Property, plant and equipment, net	530,467	534,469
Goodwill	3,095,798	3,048,405
Other intangible assets with indefinite lives	57,346	36,451
Finite-lived intangible assets, net	1,811,951	1,834,225
Deferred financing costs, net, and other non-current assets	89,383	108,857
Investments in unconsolidated entities	96,197	90,491
Deferred tax assets	9,786	8,293
<b>Total assets</b>	<b>\$ 7,100,005</b>	<b>\$ 7,067,928</b>
<b>LIABILITIES AND EQUITY</b>		
<b>Current liabilities:</b>		
Current portion of long-term debt	\$ 50,539	\$ 60,232
Current portion of capital lease obligations	5,958	6,684
Accounts payable	178,552	169,974
Accrued expenses and other current liabilities	425,379	411,919
<b>Total current liabilities</b>	<b>660,428</b>	<b>648,809</b>
<b>Long-term liabilities:</b>		
Long-term debt, net of current portion	3,808,302	3,628,675
Capital lease obligations, net of current portion	11,685	12,917
Deferred tax liabilities	390,012	428,188
Other long-term liabilities	197,781	166,635
<b>Total long-term liabilities</b>	<b>4,407,780</b>	<b>4,236,415</b>
<b>Commitments and contingencies (Note 16)</b>		
<b>Stockholders equity:</b>		
Series B preferred stock, \$0.001 par value (liquidation preference: \$709,763 at June 30, 2013 and December 31, 2012); Authorized: 2,300 shares; Issued: 2,065 shares at June 30, 2013 and December 31, 2012; Outstanding: 1,774 shares at June 30, 2013 and December 31, 2012	606,468	606,468

Edgar Filing: ALERE INC. - Form 10-Q

Common stock, \$0.001 par value; Authorized: 200,000 shares; Issued: 89,036 shares at June 30, 2013 and 88,576 shares at December 31, 2012; Outstanding: 81,357 shares at June 30, 2013 and 80,897 shares at December 31, 2012	89	89
Additional paid-in capital	3,304,273	3,299,935
Accumulated deficit	(1,613,092)	(1,564,973)
Treasury stock, at cost, 7,679 shares at June 30, 2013 and December 31, 2012	(184,971)	(184,971)
Accumulated other comprehensive income (loss)	(85,195)	23,874
<b>Total stockholders equity</b>	<b>2,027,572</b>	<b>2,180,422</b>
Non-controlling interests	4,225	2,282
<b>Total equity</b>	<b>2,031,797</b>	<b>2,182,704</b>
<b>Total liabilities and equity</b>	<b>\$ 7,100,005</b>	<b>\$ 7,067,928</b>

The accompanying notes are an integral part of these consolidated financial statements.



**Table of Contents****ALERE INC. AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF CASH FLOWS**

(unaudited)

(in thousands)

	<b>Six Months Ended June 30,</b>	
	<b>2013</b>	<b>2012</b>
<b>Cash Flows from Operating Activities:</b>		
Net loss	\$ (47,877)	\$ (11,850)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs	10,176	10,731
Depreciation and amortization	213,904	211,622
Non-cash charges for sale of inventories revalued at the date of acquisition	1,172	4,681
Non-cash stock-based compensation expense	8,800	8,242
Impairment of inventory	26	5
Impairment of long-lived assets	2,815	219
(Gain) loss on sale of fixed assets	1,301	(5,872)
Equity earnings of unconsolidated entities, net of tax	(7,485)	(7,410)
Deferred income taxes	(44,052)	(27,400)
Loss on extinguishment of debt	35,603	
Other non-cash items	(727)	(883)
Changes in assets and liabilities, net of acquisitions:		
Accounts receivable, net	(38,326)	(5,431)
Inventories, net	(52,104)	(4,412)
Prepaid expenses and other current assets	(3,319)	16,866
Accounts payable	11,850	(14,247)
Accrued expenses and other current liabilities	24,846	(366)
Other non-current liabilities	(17,844)	(8,265)
<b>Net cash provided by operating activities</b>	<b>98,759</b>	<b>166,230</b>
<b>Cash Flows from Investing Activities:</b>		
(Increase) decrease in restricted cash	(6,843)	5,888
Purchases of property, plant and equipment	(64,617)	(69,461)
Proceeds from sale of property, plant and equipment	4,640	21,677
Cash paid for acquisitions, net of cash acquired	(165,963)	(310,240)
Cash received from equity method investments	10,574	6,556
Cash paid for marketable securities		226
(Increase) decrease in other assets	17,013	(7,714)
<b>Net cash used in investing activities</b>	<b>(205,196)</b>	<b>(353,068)</b>
<b>Cash Flows from Financing Activities:</b>		
Cash paid for financing costs	(9,018)	(2,013)
Cash paid for contingent purchase price consideration	(26,638)	(6,500)
Proceeds from issuance of common stock, net of issuance costs	7,772	8,697
Proceeds from issuance of long-term debt	435,467	199,234
Payments on long-term debt	(437,816)	(29,884)
Net proceeds under revolving credit facilities	166,540	42,487
Payments on short-term debt		(6,240)

Edgar Filing: ALERE INC. - Form 10-Q

Cash paid for dividends	(10,646)	(10,646)
Excess tax benefits on exercised stock options	166	210
Principal payments on capital lease obligations	(3,488)	(3,319)
Other	(18,953)	(2,577)
<b>Net cash provided by financing activities</b>	103,386	189,449
Foreign exchange effect on cash and cash equivalents	(4,748)	1,955
Net increase (decrease) in cash and cash equivalents	(7,799)	4,566
Cash and cash equivalents, beginning of period	328,346	299,173
<b>Cash and cash equivalents, end of period</b>	\$ 320,547	\$ 303,739

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents****ALERE INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(unaudited)

**(1) Basis of Presentation of Financial Information**

The accompanying consolidated financial statements of Alere Inc. are unaudited. In the opinion of management, the unaudited consolidated financial statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations, comprehensive income and cash flows. Our audited consolidated financial statements for the year ended December 31, 2012 included information and footnotes necessary for such presentation and were included in our Annual Report on Form 10-K, as amended, filed with the Securities and Exchange Commission, or SEC, on March 1, 2013. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and notes thereto for the year ended December 31, 2012.

Certain reclassifications of prior period amounts have been made to conform to current period presentation. These reclassifications had no effect on net income or equity.

Certain amounts presented may not recalculate directly, due to rounding.

**(2) Cash and Cash Equivalents**

We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At June 30, 2013, our cash equivalents consisted of money market funds.

**(3) Inventories**

Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands):

	June 30, 2013	December 31, 2012
Raw materials	\$ 108,032	\$ 99,498
Work-in-process	83,427	89,895
Finished goods	165,294	147,728
	\$ 356,753	\$ 337,121

**(4) Stock-based Compensation**

We recorded stock-based compensation expense in our consolidated statements of operations for the three and six months ended June 30, 2013 and 2012, respectively, as follows (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2013	2012	2013	2012
Cost of net revenue	\$ 278	\$ 263	\$ 510	\$ 532
Research and development	783	856	1,530	1,627
Sales and marketing	906	913	1,622	1,830

Edgar Filing: ALERE INC. - Form 10-Q

General and administrative	2,710	2,336	5,138	4,253
	4,677	4,368	8,800	8,242
Benefit for income taxes	(496)	(874)	(1,358)	(1,415)
	\$ 4,181	\$ 3,494	\$ 7,442	\$ 6,827

**Table of Contents****(5) Net Loss per Common Share**

The following table sets forth the computation of basic and diluted net loss per common share for the periods presented (in thousands, except per share data):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2013	2012	2013	2012
<b>Numerator:</b>				
Net loss	\$ (60,302)	\$ (12,879)	\$ (47,877)	\$ (11,850)
Preferred stock dividends	(5,309)	(5,279)	(10,559)	(10,588)
Less: Net income (loss) attributable to non-controlling interest	267	36	242	(149)
<b>Net loss available to common stockholders</b>	<b>\$ (65,878)</b>	<b>\$ (18,194)</b>	<b>\$ (58,678)</b>	<b>\$ (22,289)</b>
<b>Denominator:</b>				
Weighted-average common shares outstanding basic and diluted	81,311	80,375	81,255	80,307
Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries	\$ (0.81)	\$ (0.23)	\$ (0.72)	\$ (0.28)

The following potential dilutive securities were not included in the calculation of diluted net loss per common share because the inclusion thereof would be antidilutive (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2013	2012	2013	2012
<b>Denominator:</b>				
Options to purchase shares of common stock	9,798	9,022	9,798	9,022
Warrants	4	110	4	110
Conversion shares related to 3% convertible senior subordinated notes	3,411	3,411	3,411	3,411
Conversion shares related to subordinated convertible promissory notes	27	27	27	27
Conversion shares related to Series B convertible preferred stock	10,239	10,239	10,239	10,239
<b>Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding</b>	<b>24,097</b>	<b>23,355</b>	<b>24,097</b>	<b>23,355</b>

**(6) Stockholders Equity and Non-controlling Interests***(a) Preferred Stock*

For the three and six months ended June 30, 2013, Series B preferred stock dividends amounted to \$5.3 million and \$10.6 million, respectively, and for the three and six months ended June 30, 2012, Series B preferred stock dividends amounted to \$5.3 million and \$10.6 million, respectively, which reduced earnings available to common stockholders for purposes of calculating net loss per common share for each of the respective periods. As of July 15, 2013, payments have been made covering all dividend periods through June 30, 2013.

The Series B preferred stock dividends for the three and six months ended June 30, 2013 and 2012 were paid in cash.

**Table of Contents***(b) Changes in Stockholders' Equity and Non-controlling Interests*

A summary of the changes in stockholders' equity and non-controlling interests comprising total equity for the six months ended June 30, 2013 and 2012 is provided below (in thousands):

	Six Months Ended June 30,					
	2013		2012			
	Total	Non-	Total	Total	Non-	Total
	Stockholders	controlling	Equity	Stockholders	controlling	Equity
	Equity	Interests		Equity	Interests	
Equity, beginning of period	\$ 2,180,422	\$ 2,282	\$ 2,182,704	\$ 2,229,234	\$ 2,340	\$ 2,231,574
Exercise of common stock options, warrants and shares issued under employee stock purchase plan	7,772		7,772	8,697		8,697
Preferred stock dividends	(10,646)		(10,646)	(10,646)		(10,646)
Stock-based compensation related to grants of common stock options	8,800		8,800	8,242		8,242
Excess tax benefits on exercised stock options	(1,589)		(1,589)	(261)		(261)
Non-controlling interest from acquisition		1,701	1,701			
Purchase of subsidiary shares from non-controlling interests				(35,079)		(35,079)
Net income (loss)	(48,119)	242	(47,877)	(11,701)	(85)	(11,786)
Total other comprehensive income (loss)	(109,068)		(109,068)	287		287
Equity, end of period	\$ 2,027,572	\$ 4,225	\$ 2,031,797	\$ 2,188,773	\$ 2,255	\$ 2,191,028

**(7) Business Combinations**

Acquisitions are accounted for using the acquisition method and the acquired companies' results have been included in the accompanying consolidated financial statements from their respective dates of acquisition. During the three and six months ended June 30, 2013, we expensed acquisition-related costs of \$0.4 million and \$1.3 million, respectively, in general and administrative expense. During the three and six months ended June 30, 2012, we expensed acquisition-related costs of \$3.8 million and \$5.3 million, respectively, in general and administrative expense.

Our business acquisitions have historically been made at prices above the fair value of the assets acquired and liabilities assumed, resulting in goodwill, based on our expectations of synergies and other benefits of combining the businesses. These synergies and benefits include elimination of redundant facilities, functions and staffing; use of our existing commercial infrastructure to expand sales of the products of the acquired businesses; and use of the commercial infrastructure of the acquired businesses to expand product sales in a cost-efficient manner.

Net assets acquired are recorded at their fair value and are subject to adjustment upon finalization of the fair value analysis. We are not aware of any information that indicates the final fair value analysis will differ materially from the preliminary estimates. The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the intangible assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets based on patterns on which the respective economic benefits are expected to be realized.

*(a) Acquisitions in 2013**(i) Epocal*

On February 1, 2013, we acquired Epocal, Inc., or Epocal, located in Ottawa, Canada, a provider of technologies that support blood gas and electrolyte testing at the point of care. The preliminary aggregate purchase price was approximately \$248.5 million, which consisted of \$173.5 million in cash and a contingent consideration obligation with an aggregate acquisition date fair value of \$75.0 million. The operating results of Epocal are included in our professional diagnostics reporting unit and business segment. The amount allocated to goodwill from this acquisition is not deductible for tax purposes.



**Table of Contents***(ii) Other acquisitions in 2013*

During the six months ended June 30, 2013, we acquired the following businesses for a preliminary aggregate purchase price of \$46.5 million, which included cash payments totaling \$35.4 million, contingent consideration obligations with an aggregate acquisition date fair value of \$0.8 million, deferred purchase price consideration with an acquisition date fair value of \$0.6 million and an \$8.1 million bargain purchase gain.

certain assets of PT Mega Medika Mandiri, or Mega Medika, located in South Jakarta, Indonesia, a distributor of infectious disease products to the Indonesian marketplace as well as materials for vaccines to a pharmaceutical customer (Acquired January 2013)

Discount Diabetic, LLC, or Discount Diabetic, located in Phoenix, Arizona, a provider of blood glucose monitoring products, including diabetes testing systems and test strips and other products (Acquired April 2013)

the Medicare fee for service assets of Liberty Medical, or the Liberty business, located in Port St. Lucie, Florida, a leading mail order provider of diabetes testing supplies serving the needs of both Type 1 and Type 2 diabetic patients (Acquired April 2013)

51% share in Cardio Selfcare B.V., or Cardio Selfcare, located in Ede, the Netherlands, a developer of innovative software for the healthcare industry that develops and licenses software and sells medical devices to enable patients to perform medical self-care, including thrombosis self-care (Acquired May 2013)

The operating results of Mega Medika, Discount Diabetic, the Liberty business and Cardio Selfcare are included in our professional diagnostics reporting unit and business segment.

Our consolidated statement of operations for the three and six months ended June 30, 2013 included revenue totaling approximately \$32.5 million and \$32.9 million, respectively, related to these businesses. Goodwill has been recognized in the Mega Medika and Cardio Selfcare acquisitions and amounted to approximately \$0.9 million. The goodwill related to the Mega Medika acquisition is deductible for tax purposes.

With respect to our acquisition of the Liberty business, the purchase price of the acquisition has been allocated to the net tangible and intangible assets acquired, with the excess of the fair value of assets acquired over the purchase price recorded as a bargain purchase gain. The \$8.1 million bargain purchase gain has been recorded in other income (expense), net in our consolidated statement of operations and is not recognized for tax purposes. The bargain purchase gain resulted from our operating cost structure which we believe will allow us to operate this business more cost effectively than the sellers.

A summary of the preliminary fair values of the net assets acquired for the acquisitions consummated in 2013 is as follows (in thousands):

	<b>Epocal</b>	<b>Other</b>	<b>Total</b>
Current assets <sup>(1)</sup>	\$ 12,111	\$ 10,848	\$ 22,959
Property, plant and equipment	1,267	1,669	2,936
Goodwill	99,443	939	100,382
Intangible assets	164,400	41,468	205,868
Other non-current assets	17,610	29	17,639
Total assets acquired	294,831	54,953	349,784
Current liabilities	2,643	2,603	5,246
Non-current liabilities	43,727	5,804	49,531
Total liabilities assumed	46,370	8,407	54,777



Edgar Filing: ALERE INC. - Form 10-Q

Net assets acquired	248,461	46,546	295,007
Less:			
Contingent consideration	75,000	809	75,809
Fair value of non-controlling interest		1,683	1,683
Bargain purchase gain		8,062	8,062
Deferred purchase price consideration		618	618
Cash paid	\$ 173,461	\$ 35,374	\$ 208,835

(1) Includes approximately \$3.1 million of acquired cash.

**Table of Contents**

The following are the intangible assets acquired and their respective fair values and weighted-average useful lives (dollars in thousands):

	Epocal	Other	Total	Weighted-average Useful Life
Core technology and patents	\$ 119,700	\$	\$ 119,700	20.0 years
Software		515	515	10.0 years
Trademarks and trade names	20,500	10	20,510	19.2 years
Customer relationships		35,127	35,127	11.4 years
Other		5,816	5,816	3.0 years
In-process research and development	24,200		24,200	N/A
<b>Total intangible assets</b>	<b>\$ 164,400</b>	<b>\$ 41,468</b>	<b>\$ 205,868</b>	

*(b) Acquisitions in 2012*

During 2012, we acquired the following businesses for a preliminary aggregate purchase price of \$494.5 million, which included cash payments totaling \$418.9 million and contingent consideration obligations with aggregate acquisition date fair values of \$75.6 million.

Reatrol Comercializacao De Produtos De Saude, LDA, subsequently renamed Alere Lda, located in Vila Nova de Gaia, Portugal, a distributor of products for drugs of abuse testing (Acquired January 2012)

Kullgren Holding AB, or Kullgren, located in Gensta, Sweden, a company that manufactures and distributes high-quality intimacy and pharmaceutical products (Acquired February 2012)

Wellogic ME FZ-LLC, or Wellogic UAE, located in Dubai, United Arab Emirates, a company that provides development services to Alere Wellogic, LLC, which acquired the assets of Method Factory, Inc. (d/b/a Wellogic), or Wellogic, in December 2011 (Acquired February 2012)

certain assets, primarily including customer and patient lists, of AmMed Direct LLC, or AmMed, located near Nashville, Tennessee, a privately-owned mail-order provider of home-diabetes testing products and supplies (Acquired March 2012)

eScreen, Inc., or eScreen, headquartered in Overland Park, Kansas, a technology-enabled provider of employment drug screening solutions for hiring and maintaining healthier and more efficient workforces (Acquired April 2012)

MedApps Holding Company, Inc., or MedApps, headquartered in Scottsdale, Arizona, a developer of innovative remote health monitoring solutions that deliver efficient cost-effective connectivity between patient, care provider and electronic medical records (Acquired July 2012)

Amedica Biotech, Inc., or Amedica, located in Hayward, California, a company focused on the development and manufacture of in vitro diagnostic tests (Acquired July 2012)

## Edgar Filing: ALERE INC. - Form 10-Q

DiagnosisOne, Inc., or DiagnosisOne, located in Lowell, Massachusetts, a software company that provides clinical analytics technology and data-driven content to hospitals, physician groups, insurers and governments (Acquired July 2012)

Seelen Care Laege-og & Hospitalsartikler ApS, or Seelen, located in Holstebro, Denmark, a distributor of consumables, instruments and equipment to doctors, specialists and physiotherapists (Acquired August 2012)

certain assets of Diagnostik Nord, or Diagnostik, located in Schwerin, Germany, a company focused on the sale of drug screening and in vitro diagnostic medical devices and a provider of diagnostic solutions (Acquired September 2012)

Healthcare Connections Limited, or HCC, located in Buckinghamshire, United Kingdom, an occupational health provider specializing in employment medical programs, preventative health schemes and drug and alcohol sample collection services (Acquired November 2012)

the diagnostic division of Medial spol. s.r.o., subsequently renamed Alere s.r.o., located in Prague, Czech Republic, a distributor of laboratory diagnostic devices, devices operating in the point-of-care testing regime, diagnostic kits and tests for biochemistry, hematology, and microbiology (Acquired November 2012)

certain assets of Quantum Diagnostics, or Quantum Australia, located in Australia, an on-line medical supply company that provides a range of affordable drug and alcohol tests for personal, business and professional medical use (Acquired November 2012)

certain assets of NationsHealth, Inc., or NationsHealth, headquartered in Sunrise, Florida, a privately-owned mail-order provider of diabetes home-testing products and supplies, and a share acquisition of NationsHealth's subsidiary in the Philippines, or NationsHealth Philippines (Acquired December 2012)

Branan Medical Corporation, or Branan, headquartered in Irvine, California, a manufacturer of drugs of abuse testing products (Acquired December 2012)

**Table of Contents**

The operating results of Alere Lda, AmMed, eScreen, MedApps, Amedica, Seelen, Diagnostik, HCC, Alere s.r.o., Quantum Australia, NationsHealth and Branan are included in our professional diagnostics reporting unit and business segment. The operating results of Wellogic UAE and DiagnosisOne are included in our health information solutions reporting unit and business segment. The operating results of Kullgren are included in our consumer diagnostics reporting unit and business segment.

Our consolidated statement of operations for the three and six months ended June 30, 2012 included revenue totaling approximately \$10.6 million and \$11.9 million, respectively, related to the businesses that were acquired during that period. Goodwill has been recognized in all of these acquisitions and amounted to approximately \$249.3 million. Goodwill related to the acquisitions of AmMed, Diagnostik and the U.S.-based assets of NationsHealth, which totaled \$8.8 million, is deductible for tax purposes. The goodwill related to the remaining 2012 acquisitions is not deductible for tax purposes.

A summary of the preliminary fair values of the net assets acquired for the acquisitions consummated in 2012 is as follows (in thousands):

Current assets <sup>(1)</sup>	\$ 47,201
Property, plant and equipment	9,029
Goodwill	249,294
Intangible assets	325,223
Other non-current assets	8,662
<b>Total assets acquired</b>	<b>639,409</b>
<b>Current liabilities</b>	<b>28,307</b>
Non-current liabilities	116,580
<b>Total liabilities assumed</b>	<b>144,887</b>
Net assets acquired	494,522
Less:	
Contingent consideration	75,620
<b>Cash paid</b>	<b>\$ 418,902</b>

<sup>(1)</sup> Includes approximately \$3.8 million of acquired cash.

The following are the intangible assets acquired and their respective fair values and weighted-average useful lives (dollars in thousands):

	Amount	Weighted-average Useful Life
Core technology and patents	\$ 148,103	18.7 years
Trademarks and trade names	19,390	18.3 years
Customer relationships	136,485	18.1 years
Non-competition agreements	1,118	5.1 years
Other	15,227	9.2 years
In-process research and development	4,900	N/A
<b>Total intangible assets</b>	<b>\$ 325,223</b>	

**(8) Restructuring Plans**

## Edgar Filing: ALERE INC. - Form 10-Q

The following table sets forth aggregate restructuring charges recorded in our consolidated statements of operations for the three and six months ended June 30, 2013 and 2012 (in thousands):

<b>Statement of Operations Caption</b>	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2013</b>	<b>2012</b>	<b>2013</b>	<b>2012</b>
Cost of net revenue	\$ 729	\$ 25	\$ 1,352	\$ 989
Research and development	645	14	645	638
Sales and marketing	159	200	1,258	1,027
General and administrative	6,511	1,126	8,681	4,239
<b>Total operating expenses</b>	<b>8,044</b>	<b>1,365</b>	<b>11,936</b>	<b>6,893</b>

**Table of Contents**

Statement of Operations Caption	Three Months Ended June 30,		Six Months Ended June 30,	
	2013	2012	2013	2012
Interest expense, including amortization of original issue discounts and deferred financing costs	62	50	117	110
Total charges	\$ 8,106	\$ 1,415	\$ 12,053	\$ 7,003

*(a) 2013 Restructuring Plans*

In 2013, management developed cost reduction efforts within our professional diagnostics business segment, including businesses in our Europe and Asia Pacific regions. Additionally, management is continuing to improve efficiencies within our health information solutions business segment, including winding down a small portion of this business, which resulted in charges associated with the impairment of related fixed and intangible assets. The following table summarizes the restructuring activities related to our 2013 restructuring plans for the three and six months ended June 30, 2013 (in thousands):

	Three Months Ended June 30, 2013		
	Health		
	Professional Diagnostics	Information Solutions	Total
Severance-related costs	\$ 1,251	\$ (11)	\$ 1,240
Facility and transition costs	337	241	578
Cash charges	1,588	230	1,818
Fixed asset and inventory impairments		170	170
Intangible asset impairments		2,596	2,596
Total charges	\$ 1,588	\$ 2,996	\$ 4,584

	Six Months Ended June 30, 2013		
	Health		
	Professional Diagnostics	Information Solutions	Total
Severance-related costs	\$ 2,084	\$ 58	\$ 2,142
Facility and transition costs	350	241	591
Cash charges	2,434	299	2,733
Fixed asset and inventory impairments		170	170
Intangible asset impairments		2,596	2,596
Total charges	\$ 2,434	\$ 3,065	\$ 5,499

We anticipate incurring approximately \$1.0 million in additional costs under our 2013 restructuring plans related primarily to our professional diagnostics business segment in Europe and may develop additional plans over the remainder of 2013. As of June 30, 2013, \$0.4 million in severance and contract cancellation costs arising under our 2013 restructuring plans remain unpaid.

*(b) 2012 Restructuring Plans*

In 2012, management developed cost reduction plans within our professional diagnostics business segment, including the integration of our businesses in Brazil, Europe and the United States. Additionally, management developed new plans to continue our efforts to reduce costs within our health information solutions business segment, including the termination of certain projects, which resulted in charges for the impairment of related fixed and intangible assets. The following table summarizes the restructuring activities related to our 2012 restructuring plans for the

## Edgar Filing: ALERE INC. - Form 10-Q

three and six months ended June 30, 2013 and 2012 and since inception (in thousands):

<b>Professional Diagnostics</b>	<b>Three Months Ended</b>		<b>Six Months Ended</b>		<b>Since Inception</b>
	<b>June 30,</b>		<b>June 30,</b>		
	<b>2013</b>	<b>2012</b>	<b>2013</b>	<b>2012</b>	
Severance-related costs	\$ 26	\$ 345	\$ 88	\$ 2,318	\$ 4,820
Facility and transition costs	19		82		201

**Table of Contents**

	Three Months Ended		Six Months Ended		Since Inception
	June 30,		June 30,		
Professional Diagnostics	2013	2012	2013	2012	
Cash charges	45	345	170	2,318	5,021
Fixed asset impairments					304
<b>Total charges</b>	<b>\$ 45</b>	<b>\$ 345</b>	<b>\$ 170</b>	<b>\$ 2,318</b>	<b>\$ 5,325</b>

	Three Months Ended		Six Months Ended		Since Inception
	June 30,		June 30,		
Health Information Solutions	2013	2012	2013	2012	
Severance-related costs	\$ 529	\$ 422	\$ 2,348	\$ 1,219	\$ 5,393
Facility and transition costs	3,612	125	4,271	125	5,505
Other exit costs	32		52		67
Cash charges	4,173	547	6,671	1,344	10,965
Fixed asset and inventory impairments	75		75		2,764
Intangible asset impairments					2,988
Other non-cash charges	(908)	(5)	(953)		(984)
<b>Total charges</b>	<b>\$ 3,340</b>	<b>\$ 542</b>	<b>\$ 5,793</b>	<b>\$ 1,344</b>	<b>\$ 15,733</b>

We anticipate incurring approximately \$0.6 million in additional transition and other facility costs under these plans related primarily to our health information solutions business segment through 2014. As of June 30, 2013, \$5.7 million in severance and exit costs under these plans remain unpaid.

*(c) 2011, 2010 and 2008 Restructuring Plans*

In 2011, management executed a company-wide cost reduction plan which impacted our corporate and other business segment, as well as the health information solutions and professional diagnostics business segments. Management also developed plans within our professional diagnostics business segment to consolidate operating activities among certain of our U.S., European and Asia Pacific subsidiaries, including transferring the manufacturing of our Panbio products from Australia to our Standard Diagnostics facility in South Korea and eliminating redundant costs among our newly-acquired Axis-Shield subsidiaries. Additionally, within our health information solutions business segment, management executed plans to further reduce costs and improve efficiencies, as well as cease operations at our GeneCare Medical Genetics Center, Inc., or GeneCare, facility in Chapel Hill, North Carolina and transfer the majority of our Quality Assured Services, Inc. operation in Orlando, Florida to our facility in Livermore, California.

In 2010, management developed several plans to reduce costs and improve efficiencies within our health information solutions and professional diagnostics business segments. Additionally in 2008, management developed and initiated plans to transition the business of Cholestech to our San Diego, California facility.

The following table summarizes the restructuring activities related to our 2011, 2010 and 2008 restructuring plans for the three and six months ended June 30, 2013 and 2012 and since inception (in thousands):

	Three Months Ended		Six Months Ended		Since Inception
	June 30,		June 30,		
Professional Diagnostics	2013	2012	2013	2012	
Severance-related costs	\$ (54)	\$ 310	\$ 196	\$ 2,275	\$ 19,909



Edgar Filing: ALERE INC. - Form 10-Q

Facility and transition costs	161	161	330	884	7,557
Other exit costs	15	17	31	36	729
Cash charges	122	488	557	3,195	28,195
Fixed asset and inventory impairments				134	6,374
Total charges	\$ 122	\$ 488	\$ 557	\$ 3,329	\$ 34,569

**Table of Contents**

Health Information Solutions	Three Months Ended June 30,		Six Months Ended June 30,		Since Inception
	2013	2012	2013	2012	
Severance-related costs	\$	\$	\$	\$	\$ 6,901
Facility and transition costs		(87)		(173)	8,010
Other exit costs	15	33	34	74	546
Cash charges	15	(54)	34	(99)	15,457
Fixed asset and inventory impairments		85		85	1,114
Intangible asset impairments					2,935
Other non-cash charges					761
Total charges	\$ 15	\$ 31	\$ 34	\$ (14)	\$ 20,267

Corporate and Other	Three Months Ended June 30,		Six Months Ended June 30,		Since Inception
	2013	2012	2013	2012	
Severance-related costs	\$	\$ 9	\$	\$ 26	\$ 1,219
Cash charges		9		26	1,219
Fixed asset and inventory impairments					3
Total charges	\$	\$ 9	\$	\$ 26	\$ 1,222

We anticipate incurring approximately \$1.1 million in additional costs under these plans related primarily to our professional diagnostics business segment. A majority of these additional costs relate to the transfer of the Panbio product manufacturing to Korea and are for severance and facility exit costs. We may also incur impairment charges on assets as plans are finalized. We do not anticipate incurring significant additional costs under these plans related to our health information solutions business segment. As of June 30, 2013, \$2.5 million in cash charges remain unpaid, primarily related to facility lease obligations.

*(d) Restructuring Reserves*

The following table summarizes our restructuring reserves related to the plans described above, of which \$6.3 million is included in accrued expenses and other current liabilities and \$2.3 million is included in other long-term liabilities on our accompanying consolidated balance sheets (in thousands):

	Severance- related Costs	Facility and Transition Costs	Other Exit Costs	Total
Balance, December 31, 2012	\$ 3,167	\$ 2,429	\$ 622	\$ 6,218
Cash charges	4,774	5,274	117	10,165
Payments	(5,462)	(2,042)	(146)	(7,650)
Currency adjustments	(166)	(8)		(174)
Balance, June 30, 2013	\$ 2,313	\$ 5,653	\$ 593	\$ 8,559

**(9) Long-term Debt**

## Edgar Filing: ALERE INC. - Form 10-Q

We had the following long-term debt balances outstanding (in thousands):

	<b>June 30, 2013</b>	<b>December 31, 2012</b>
A term loans <sup>(1)(2)</sup>	\$ 855,313	\$ 878,438
B term loans <sup>(1)</sup>	908,813	913,438
Incremental B-1 term loans <sup>(1)</sup>	246,250	247,500
Incremental B-2 term loans <sup>(1)</sup>	195,891	196,739
Revolving line of credit <sup>(1)</sup>	197,500	22,500
7.25% Senior notes	450,000	450,000
7.875% Senior notes		1,809
9% Senior subordinated notes		392,933
8.625% Senior subordinated notes	400,000	400,000

**Table of Contents**

	June 30, 2013	December 31, 2012
6.5% Senior subordinated notes	425,000	
3% Convertible senior subordinated notes	150,000	150,000
Other lines of credit	405	31,957
Other	29,669	3,593
	3,858,841	3,688,907
Less: Current portion	(50,539)	(60,232)
	\$ 3,808,302	\$ 3,628,675

(1) Incurred under our secured credit facility.

(2) Includes A term loans and Delayed Draw term loans under our secured credit facility.

In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying consolidated statements of operations for the three and six months ended June 30, 2013 and 2012, respectively, as follows (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2013	2012	2013	2012
Secured credit facility <sup>(1)</sup>	\$ 25,657	\$ 27,097	\$ 52,932	\$ 49,948
7.25% Senior notes	8,480		16,836	
7.875% Senior notes <sup>(2)</sup>	1	5,755	137	11,513
9% Senior subordinated notes <sup>(3)</sup>	43,649	10,363	54,043	20,717
8.625% Senior subordinated notes	9,274	9,275	18,547	18,549
6.5% Senior subordinated notes	3,013		3,013	
3% Senior subordinated convertible notes	1,246	1,246	2,492	2,492
	\$ 91,320	\$ 53,736	\$ 148,000	\$ 103,219

(1) Includes A term loans, including the Delayed-Draw term loans; B term loans; Incremental B-1 term loans; Incremental B-2 term loans revolving line of credit loans. For the three and six months ended June 30, 2013, the amounts include \$0.8 million and \$1.8 million, respectively, related to the amortization of fees paid for certain debt modifications. For the three and six months ended June 30, 2012, the amount includes \$1.3 million and \$2.6 million, respectively, related to the amortization of fees paid for certain debt modifications.

(2) For the six months ended June 30, 2013, this amount includes an approximate \$0.2 million loss recorded in connection with the repurchase of our 7.875% senior notes.

(3) An approximate \$35.6 million loss in connection with the repurchase of our 9% senior subordinated notes has been included in each of the three and six-month periods for 2013. Included in the \$35.6 million is \$19.0 million related to tender offer consideration and call premium which has been classified within cash flow from financing activities in our consolidated statement of cash flows.

(a) *Secured Credit Facility*

The following summarizes the material terms of our secured credit facility that have changed significantly since December 31, 2012. All other terms of our secured credit facility as described in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2012, but omitted below, have not changed since that date.

On March 22, 2013, we and certain of our subsidiaries entered into a fourth amendment to the credit agreement that governs our secured credit facility, or the credit agreement. The fourth amendment provides for 50 basis point reductions in the interest rate margins applicable to the B term loans, the Incremental B-1 term loans and the Incremental B-2 term loans and certain other changes. Under the terms of the credit agreement as amended by the fourth amendment, the B term loans, the Incremental B-1 term loans and the Incremental B-2 term loans bear interest at a rate per annum of, at our option, either (i) the Base Rate, as defined in the credit agreement, plus an applicable margin, which varies

## Edgar Filing: ALERE INC. - Form 10-Q

between 2.00% and 2.75% depending on our consolidated secured leverage ratio, or (ii) the Eurodollar Rate, as defined in the credit agreement, plus an applicable margin, which varies between 3.00% and 3.75% depending on our consolidated secured leverage ratio. Interest on B term loans, Incremental B-1 term loans and Incremental B-2 term loans based on the Eurodollar Rate is subject to a 1.00% floor with respect to the base Eurodollar Rate. Furthermore, under the terms of the credit agreement as amended by the fourth amendment, we may make optional prepayments of the term loans under our secured credit facility from time to time without any premium or penalty, except that if, on or before September 22, 2013, we repay or prepay any B term loans, Incremental B-1 term loans or Incremental B-2 term loans with the

---

**Table of Contents**

proceeds of, or convert any B term loans, Incremental B-1 term loans or Incremental B-2 term loans into, any new term loans bearing interest with an effective yield (as defined in the credit agreement) less than the effective yield applicable to the B term loans, the Incremental B-1 term loans or the Incremental B-2 term loans, as applicable, we must pay a premium equal to 1.0% of the principal amount of the B term loans, Incremental B-1 term loans or Incremental B-2 term loans so repaid, prepaid or converted.

*(b) 6.5% Senior Subordinated Notes*

On May 24, 2013, we sold a total of \$425.0 million aggregate principal amount of 6.5% senior subordinated notes due 2020, or the 6.5% senior subordinated notes, in a private placement to initial purchasers, who agreed to resell the notes only to qualified institutional buyers and to persons outside the United States; we sold the 6.5% senior subordinated notes at an initial offering price of 100%. Net proceeds from this offering amounted to \$417.7 million, which were net of the underwriters' commissions and offering expenses totaling approximately \$7.3 million.

The 6.5% senior subordinated notes were issued under a supplemental indenture dated May 24, 2013, or the 6.5% Indenture. The 6.5% senior subordinated notes accrue interest at the rate of 6.5% per annum. Interest on the 6.5% senior subordinated notes is payable semi-annually on June 15 and December 15, beginning on December 15, 2013. The 6.5% senior subordinated notes mature on June 15, 2020, unless earlier redeemed.

We may, at our option, redeem the 6.5% senior subordinated notes, in whole or part, at any time (which may be more than once) on or after June 15, 2016, by paying the principal amount of the notes being redeemed plus a declining premium, plus accrued and unpaid interest to (but excluding) the redemption date. The premium declines from 3.250% during the twelve months on and after June 15, 2016 to 1.625% during the twelve months on and after June 15, 2017 to zero on and after June 15, 2018. In addition, we may, at our option, at any time (which may be more than once) before May 24, 2015, redeem up to 10% of the aggregate principal amount of the 6.5% senior subordinated notes in each of the two twelve-month periods preceding May 24, 2015 at a redemption price of 103% of the principal amount thereof plus accrued and unpaid interest to (but excluding) the redemption date. In addition, at any time (which may be more than once) prior to June 15, 2016, we may, at our option, redeem up to 35% of the aggregate principal amount of the 6.5% senior subordinated notes with money that we raise in certain equity offerings, so long as (i) we pay 106.5% of the principal amount of the notes being redeemed, plus accrued and unpaid interest to (but excluding) the redemption date; (ii) we redeem the 6.5% senior subordinated notes within 90 days of completing such equity offering; and (iii) at least 65% of the aggregate principal amount of the 6.5% senior subordinated notes remains outstanding afterwards. In addition, at any time (which may be more than once) prior to June 15, 2016, we may, at our option, redeem some or all of the 6.5% senior subordinated notes by paying the principal amount of the 6.5% senior subordinated notes being redeemed plus a make-whole premium, plus accrued and unpaid interest to (but excluding) the redemption date.

If a change of control occurs, subject to specified conditions, we must give holders of the 6.5% senior subordinated notes an opportunity to sell their notes to us at a purchase price of 101% of the principal amount of the notes, plus accrued and unpaid interest to (but excluding) the date of the purchase.

If we or our subsidiaries engage in asset sales, we or they generally must either invest the net cash proceeds from such sales in our or their businesses within a specified period of time, repay senior indebtedness or make an offer to purchase a principal amount of the 6.5% senior subordinated notes equal to the excess net cash proceeds, subject to certain exceptions. The purchase price of the 6.5% senior subordinated notes would be 100% of their principal amount, plus accrued and unpaid interest.

The 6.5% Indenture provides that we and our subsidiaries must comply with various customary covenants. These covenants limit our ability, and the ability of our subsidiaries, to, among other things, incur additional debt; pay dividends on our or their capital stock or redeem, repurchase or retire our or their capital stock or subordinated debt; make certain investments; create liens on assets; transfer or sell assets; engage in transactions with our or their affiliates; create restrictions on the ability of our or their subsidiaries to pay dividends or make loans, asset transfers or other payments to us and our subsidiaries; issue capital stock of subsidiaries; engage in any business, other than our or their existing businesses and related businesses; enter into sale and leaseback transactions; incur layered indebtedness; and consolidate or merge with any person (other than certain affiliates) or transfer all or substantially all of our assets or the aggregate assets of us and our subsidiaries. These covenants are subject to certain important exceptions and qualifications, which are set forth in the 6.5% Indenture. At any time the 6.5% senior subordinated notes are rated investment grade, certain covenants will be suspended with respect to them.

The 6.5% Indenture contains customary events of default entitling the trustee or the holders of the 6.5% senior subordinated notes to declare all amounts owed pursuant to the 6.5% senior subordinated notes immediately payable if any such event of default occurs.

## Edgar Filing: ALERE INC. - Form 10-Q

The 6.5% senior subordinated notes are our senior subordinated unsecured obligations, are subordinated in right of payment to all of our existing and future senior debt, including our borrowings under our secured credit facility and our 7.25% senior notes, and

**Table of Contents**

are equal in right of payment with our 8.625% senior subordinated notes and our 3% convertible senior subordinated notes. Our obligations under the 6.5% senior subordinated notes and the 6.5% Indenture are fully and unconditionally guaranteed, jointly and severally, on a senior subordinated unsecured basis by certain of our domestic subsidiaries, and the obligations of such domestic subsidiaries under their guarantees are subordinated in right of payment to all of their existing and future senior debt. See Note 19 for guarantor financial information.

*(c) 9% Senior Subordinated Notes*

On May 24, 2013, we used \$200.6 million of the net proceeds of our sale of the 6.5% senior subordinated notes to purchase \$190.6 million outstanding principal amount of our 9% senior subordinated notes due 2016, or the 9% senior subordinated notes, pursuant to our tender offer for these notes. The purchased 9% senior subordinated notes represented approximately 47.7% of the total then-outstanding principal amount of the 9% senior subordinated notes.

On June 24, 2013, we redeemed the remaining \$209.4 million outstanding principal amount of the 9% senior subordinated notes pursuant to our optional redemption right under the indenture under which the 9% senior subordinated notes were issued, and we subsequently terminated this indenture.

**(10) Derivative Financial Instruments**

We may manage our economic and transaction exposure to certain market-based risks through the use of derivative instruments. Our objective for holding derivative instruments has been to reduce volatility of net earnings and cash flows associated with changes in interest rates and foreign currency exchange rates. We do not hold or issue derivative financial instruments for speculative purposes.

*Foreign Currency Risk*

In connection with our acquisition of Axis-Shield, we acquired a number of foreign currency forward contracts. The specific risk hedged in these contracts was the undiscounted foreign currency spot rate risk on forecasted foreign currency revenue. As of December 31, 2012, all of the acquired foreign currency forward contracts were settled. We report the effective portion of the gain or loss on a cash flow hedge as a component of other comprehensive income, and it was subsequently reclassified into net earnings in the period in which the hedged transaction affected net earnings or the forecasted transaction was no longer probable of occurring.

The following table summarizes the effect of derivative instruments in our accompanying consolidated statement of operations (in thousands):

		<b>Amount of Loss Recognized During the Three Months Ended June 30, 2012</b>	<b>Amount of Gain Recognized During the Six Months Ended June 30, 2012</b>
	<b>Location of Gain (Loss)</b>		
<b>Derivative Instruments</b>	<b>Recognized in Income</b>		
Foreign currency forward contracts	Other comprehensive income (loss)	\$ (652)	\$ 455
Total gain (loss)	Other comprehensive income (loss)	\$ (652)	\$ 455

**(11) Fair Value Measurements**

We apply fair value measurement accounting to value our financial assets and liabilities. Fair value measurement accounting provides a framework for measuring fair value under U.S. GAAP and requires expanded disclosures regarding fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value.



## Edgar Filing: ALERE INC. - Form 10-Q

Described below are the three levels of inputs that may be used to measure fair value:

*Level 1* Quoted prices in active markets for identical assets or liabilities.

*Level 2* Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

*Level 3* Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

**Table of Contents**

The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2013 and December 31, 2012, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands):

Description	June 30, 2013	Quoted Prices in		Significant		
		Active	Markets	Other	Observable Inputs	Unobservable Inputs
		(Level 1)	(Level 2)	(Level 2)	(Level 3)	(Level 3)
<b>Assets:</b>						
Marketable securities	\$ 889	\$ 889	\$	\$		
<b>Total assets</b>	<b>\$ 889</b>	<b>\$ 889</b>	<b>\$</b>	<b>\$</b>		
<b>Liabilities:</b>						
Contingent consideration obligations <sup>(1)</sup>	\$ 233,051	\$	\$	\$	\$ 233,051	
<b>Total liabilities</b>	<b>\$ 233,051</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$ 233,051</b>	

Description	December 31, 2012	Quoted Prices in		Significant		
		Active	Markets	Other	Observable Inputs	Unobservable Inputs
		(Level 1)	(Level 2)	(Level 2)	(Level 3)	(Level 3)
<b>Assets:</b>						
Marketable securities	\$ 904	\$ 904	\$	\$		
<b>Total assets</b>	<b>\$ 904</b>	<b>\$ 904</b>	<b>\$</b>	<b>\$</b>		
<b>Liabilities:</b>						
Contingent consideration obligations <sup>(1)</sup>	\$ 176,172	\$	\$	\$	\$ 176,172	
<b>Total liabilities</b>	<b>\$ 176,172</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$ 176,172</b>	

<sup>(1)</sup> We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our consolidated statements of operations.

Changes in the fair value of our Level 3 contingent consideration obligations during the six months ended June 30, 2013 were as follows (in thousands):

Fair value of contingent consideration obligations, January 1, 2013	\$ 176,172
Acquisition date fair value of contingent consideration obligations recorded	75,815
Net reclassifications	(12)
Foreign currency	(460)
Payments	(34,739)
Present value accretion	3,402

## Edgar Filing: ALERE INC. - Form 10-Q

Adjustments, net (income) expense	12,873
-----------------------------------	--------

Fair value of contingent consideration obligations, June 30, 2013	\$ 233,051
---	------------

At June 30, 2013 and December 31, 2012, the carrying amounts of cash and cash equivalents, restricted cash, receivables, accounts payable and other current liabilities approximated their estimated fair values.

The carrying amount and estimated fair value of our long-term debt were \$3.9 billion and \$3.9 billion, respectively, at June 30, 2013. The carrying amount and estimated fair value of our long-term debt were \$3.7 billion at December 31, 2012. The estimated fair value of our long-term debt was determined using market sources that were derived from available market information (Level 2 in the fair value hierarchy) and may not be representative of actual values that could have been or will be realized in the future.

**Table of Contents****(12) Defined Benefit Pension Plan**

Our subsidiary in England, Unipath Ltd., has a defined benefit pension plan established for certain of its employees. The net periodic benefit costs are as follows (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2013	2012	2013	2012
Service cost	\$	\$	\$	\$
Interest cost	180	199	361	397
Expected return on plan assets	(154)	(153)	(309)	(305)
Amortization of prior service costs	102	104	205	208
Realized losses				
Net periodic benefit cost	\$ 128	\$ 150	\$ 257	\$ 300

**(13) Financial Information by Segment**

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of the chief executive officer and members of senior management. Our reportable operating segments are professional diagnostics, health information solutions, consumer diagnostics and corporate and other. Our operating results include license and royalty revenue which are allocated to professional diagnostics and consumer diagnostics on the basis of the original license or royalty agreement.

We evaluate performance of our operating segments based on revenue and operating income (loss). Segment information for the three and six months ended June 30, 2013 and 2012 is as follows (in thousands):

	Health		Corporate		Total
	Professional Diagnostics	Information Solutions	Consumer Diagnostics	and Other	
<b>Three Months Ended June 30, 2013:</b>					
Net revenue	\$ 603,762	\$ 134,775	\$ 25,448	\$	\$ 763,985
Operating income (loss)	\$ 72,896	\$ (11,759)	\$ 3,404	\$ (20,137)	\$ 44,404
Depreciation and amortization	\$ 86,856	\$ 20,725	\$ 1,080	\$ 273	\$ 108,934
Non-cash charge associated with acquired inventory	\$ 711	\$	\$	\$	\$ 711
Restructuring charge	\$ 1,740	\$ 6,304	\$	\$	\$ 8,044
Stock-based compensation	\$	\$	\$	\$ 4,677	\$ 4,677
<b>Three Months Ended June 30, 2012:</b>					
Net revenue	\$ 540,110	\$ 138,590	\$ 21,817	\$	\$ 700,517
Operating income (loss)	\$ 63,251	\$ (12,666)	\$ 2,699	\$ (18,930)	\$ 34,354
Depreciation and amortization	\$ 83,413	\$ 24,065	\$ 1,178	\$ 244	\$ 108,900
Restructuring charge	\$ 817	\$ 539	\$	\$ 9	\$ 1,365
Stock-based compensation	\$	\$	\$	\$ 4,368	\$ 4,368
<b>Six Months Ended June 30, 2013:</b>					
Net revenue	\$ 1,186,254	\$ 268,982	\$ 47,998	\$	\$ 1,503,234
Operating income (loss)	\$ 132,736	\$ (25,652)	\$ 5,684	\$ (37,875)	\$ 74,893
Depreciation and amortization	\$ 169,650	\$ 41,462	\$ 2,233	\$ 559	\$ 213,904
Non-cash charge associated with acquired inventory	\$ 1,172	\$	\$	\$	\$ 1,172
Restructuring charge	\$ 3,129	\$ 8,807	\$	\$	\$ 11,936
Stock-based compensation	\$	\$	\$	\$ 8,800	\$ 8,800
<b>Six Months Ended June 30, 2012:</b>					
Net revenue	\$ 1,058,467	\$ 269,374	\$ 43,805	\$	\$ 1,371,646

Edgar Filing: ALERE INC. - Form 10-Q

Operating income (loss)	\$ 133,430	\$ (32,022)	\$ 3,064	\$ (35,060)	\$ 69,412
Depreciation and amortization	\$ 160,881	\$ 47,839	\$ 2,437	\$ 465	\$ 211,622
Non-cash charge associated with acquired inventory	\$ 4,681	\$	\$	\$	\$ 4,681
Restructuring charge	\$ 5,611	\$ 1,256	\$	\$ 26	\$ 6,893

**Table of Contents**

	Professional Diagnostics	Health Information Solutions	Consumer Diagnostics	Corporate and Other	Total
Stock-based compensation	\$	\$	\$	\$ 8,242	\$ 8,242
<b>Assets:</b>					
As of June 30, 2013	\$ 6,254,068	\$ 561,786	\$ 199,423	\$ 84,728	\$ 7,100,005
As of December 31, 2012	\$ 6,214,847	\$ 593,172	\$ 192,748	\$ 67,161	\$ 7,067,928

The following tables summarize our net revenue from the professional diagnostics and health information solutions reporting segments by groups of similar products and services for the three and six months ended June 30, 2013 and 2012 (in thousands):

Professional Diagnostics Segment:	Three Months Ended June 30,		Six Months Ended June 30,	
	2013	2012	2013	2012
Cardiology	\$ 118,436	\$ 125,597	\$ 233,369	\$ 264,423
Infectious disease	157,706	137,821	347,550	288,837
Toxicology	165,884	159,922	314,933	281,662
Diabetes	74,905	36,797	124,988	64,958
Other	82,666	76,736	157,385	152,442
Net product sales and services revenue	599,597	536,873	1,178,225	1,052,322
License and royalty revenue	4,165	3,237	8,029	6,145
Professional diagnostics net revenue	\$ 603,762	\$ 540,110	\$ 1,186,254	\$ 1,058,467

Health Information Solutions Segment:	Three Months Ended June 30,		Six Months Ended June 30,	
	2013	2012	2013	2012
Disease and case management	\$ 52,578	\$ 54,512	\$ 106,704	\$ 107,894
Wellness	27,230	29,567	53,530	56,591
Women's & children's health	29,256	31,313	58,336	61,084
Patient self-testing services	25,711	23,198	50,412	43,805
Health management net revenue	\$ 134,775	\$ 138,590	\$ 268,982	\$ 269,374

**(14) Related Party Transactions**

In May 2007, we completed the formation of SPD, our 50/50 joint venture with P&G, for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiology, diabetes and oral care fields. Upon completion of the arrangement to form the joint venture, we ceased to consolidate the operating results of our consumer diagnostic products business related to the joint venture and instead account for our 50% interest in the results of the joint venture under the equity method of accounting.

We had a net payable to the joint venture of \$1.1 million as of June 30, 2013 and a net receivable from the joint venture of \$2.3 million as of December 31, 2012. Included in the \$1.1 million payable balance as of June 30, 2013 is approximately \$1.5 million of costs incurred in connection with our 2008 SPD-related restructuring plans. Included in the \$2.3 million receivable balance as of December 31, 2012 is approximately \$1.6 million of costs incurred in connection with our 2008 SPD-related restructuring plans. We have also recorded a long-term receivable totaling approximately \$12.1 million and \$14.6 million as of June 30, 2013 and December 31, 2012, respectively, related to the 2008 SPD-related restructuring plans. Additionally, customer receivables associated with revenue earned after the joint venture was completed have been classified as other receivables within prepaid and other current assets on our accompanying consolidated balance sheets in the amount of \$9.2 million and \$6.9 million as of June 30, 2013 and December 31, 2012, respectively. In connection with the joint venture arrangement, the joint venture bears the collection risk associated with these receivables. Sales to the joint venture under our manufacturing agreement totaled \$18.2 million and \$35.3 million during the three and six months ended June 30, 2013, respectively, and \$14.5 million and \$31.6 million during the three and six months ended June 30, 2012, respectively. Additionally, services revenue generated pursuant to the long-term services agreement with the joint venture totaled \$0.3 million and \$0.6 million during the three and six months ended June 30, 2013, respectively, and \$0.3 million and \$0.6 million during the three and six months ended June 30, 2012, respectively. Sales under our manufacturing agreement and

## Edgar Filing: ALERE INC. - Form 10-Q

long-term services agreement are included in net product sales and services revenue, respectively, in our accompanying consolidated statements of operations.

Under the terms of our product supply agreement, the joint venture purchases products from our manufacturing facilities in the U.K. and China. The joint venture in turn sells a portion of those tests back to us for final assembly and packaging. Once packaged,

**Table of Contents**

the tests are sold to P&G for distribution to third-party customers in North America. As a result of these related transactions, we have recorded \$9.6 million and \$7.3 million of trade receivables which are included in accounts receivable on our accompanying consolidated balance sheets as of June 30, 2013 and December 31, 2012, respectively, and \$23.1 million and \$21.3 million of trade accounts payable which are included in accounts payable on our accompanying consolidated balance sheets as of June 30, 2013 and December 31, 2012, respectively. During the six months ended June 30, 2013 and 2012, we received \$10.8 million and \$6.1 million, respectively, in cash from SPD as a return of capital.

The following table summarizes our related party balances with SPD within our consolidated balance sheets (in thousands):

<b>Balance Sheet Caption:</b>	<b>June 30, 2013</b>	<b>December 31, 2012</b>
Accounts receivable, net of allowances	\$ 9,591	\$ 7,317
Prepaid expenses and other current assets	\$ 9,209	\$ 9,161
Deferred financing costs, net, and other non-current assets	\$ 12,134	\$ 14,629
Accounts payable	\$ 23,131	\$ 21,258
Accrued expenses and other current liabilities	\$ 1,119	\$

**(15) Other Arrangements**

On February 19, 2013, we entered into an agreement with the Bill and Melinda Gates Foundation, or the Gates Foundation, whereby we were awarded a grant by the Gates Foundation in the amount of \$21.6 million to support the development and commercialization of a validated, low-cost, nucleic-acid assay for clinical Tuberculosis, or TB, detection and drug-resistance test cartridges and adaptation of an analyzer platform capable of operation in rudimentary laboratories in low-resource settings. In connection with this agreement, we also entered into a loan agreement with the Gates Foundation, or the Gates Loan Agreement, which provides for the making of subordinated term loans by the Gates Foundation to us from time to time, subject to the achievement of certain milestones, in an aggregate principal amount of up to \$20.6 million. Funding under the Gates Loan Agreement will be used in connection with the purchase of equipment for an automated high-throughput manufacturing line and other uses as necessary for the manufacture of the TB and HIV-related products. All loans under the Gates Loan Agreement are evidenced by promissory notes that we have executed and delivered to the Gates Foundation, bear interest at the rate of 3% per annum and, except to the extent earlier repaid by us, mature and are required to be repaid in full on December 31, 2019. As of June 30, 2013, we had borrowed no amounts under the Gates Loan Agreement. As of June 30, 2013, we had received approximately \$7.9 million in grant-related funding from the Gates Foundation, which was recorded as restricted cash and deferred grant funding. The deferred grant funding is classified within accrued expenses and other current liabilities on our accompanying consolidated balance sheet. As qualified expenditures are incurred under the terms of the grant, we use the deferred funding to recognize a reduction of our related qualified research and development expenditures. For the three and six months ended June 30, 2013, we recognized approximately \$1.8 million and \$2.4 million, respectively, of qualified expenditures, which were recorded as an offset to our research and development expenses.

**(16) Material Contingencies***Acquisition-related Contingent Consideration Obligations*

The following summarizes our principal contractual acquisition-related contingent consideration obligations as of June 30, 2013 that have changed significantly since December 31, 2012. Other acquisition-related contingent consideration obligations that were presented in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2012, but which are omitted below, represent those that have not changed significantly since that date.

**Accordant**

With respect to Accordant, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and cash collection targets starting after the second anniversary of the acquisition date and completed prior to the third anniversary of the acquisition date. An earn-out totaling \$4.5 million was earned and accrued as of December 31, 2012. A payment of \$1.5 million was made during each of the first and second quarters of 2013 and the remaining payment will be made in a final installment of \$1.5 million during the third quarter of 2013.



## Edgar Filing: ALERE INC. - Form 10-Q

### Alere Healthcare

With respect to Alere Healthcare, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and operating income targets during each of the calendar years 2010 through 2012. The 2012 portion of the earn-out totaling \$0.3 million, which was previously accrued at December 31, 2012, was paid during the second quarter of 2013. No further contingent consideration obligations related to this acquisition exist as of June 30, 2013.

## **Table of Contents**

### **Alere S.A.**

With respect to Alere S.A., the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and EBITDA targets during each of the calendar years 2011 through 2016. The remaining earn-out was settled for BRL 6.9 million (approximately \$3.1 million at June 30, 2013). A payment of BRL 2.9 million will be paid during the third quarter of 2013 and the remaining BRL 4.0 million will be paid in 48 equal monthly installments beginning in August 2013. The present value of the settlement totaling BRL 6.1 million (approximately \$2.8 million at June 30, 2013) was accrued at June 30, 2013. No further contingent consideration obligations related to this acquisition exist as of June 30, 2013.

### **Amedica**

With respect to Amedica, the terms of the acquisition agreement require us to make earn-out payments upon successfully meeting certain financial targets during each of the calendar years 2012 and 2013. The 2012 portion of the earn-out totaling \$6.9 million, which was previously accrued at December 31, 2012, was paid during the second quarter of 2013. The maximum remaining amount of the earn-out payments is \$8.1 million.

### **Branan**

With respect to Branan, the terms of the acquisition agreement require us to pay earn-outs upon successfully achieving various regulatory product approval milestones by the second anniversary of the acquisition date. Four milestones were achieved during 2012, resulting in an accrual totaling approximately \$2.0 million as of December 31, 2012. During the first quarter of 2013, two additional milestones were achieved, resulting in an incremental accrual of \$1.0 million. Payment of these earn-outs was made during the first quarter of 2013. The maximum remaining amount of the earn-out payments is \$2.0 million.

### **Epocal**

With respect to Epocal, the terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. The maximum amount of the earn-out payments is \$90.5 million, of which \$15.0 million was paid at the acquisition closing date. The maximum amount of the management incentive payments is \$9.4 million.

### **Immunalysis**

With respect to Immunalysis, the terms of the acquisition agreement require us to pay earn-outs upon successfully meeting certain gross profit targets during each of the calendar years 2010 through 2012. During the second quarter of 2013, it was determined that the 2012 earn-out totaling \$1.7 million had been achieved and payment was made during the same quarter. No further contingent consideration obligations related to this acquisition exist as of June 30, 2013.

Additionally, we had a contractual contingent obligation to pay up to \$3.0 million in compensation to certain executives of Immunalysis in accordance with the acquisition agreement that, to the extent earned, was paid out in connection with the contingent consideration payable to the former shareholders of Immunalysis, for each of the calendar years 2010, 2011 and 2012. Payment of the 2012 compensation totaling \$1.0 million, which was previously accrued at December 31, 2012, was made during the second quarter of 2013. No further such compensation obligations related to this acquisition exist as of June 30, 2013.

### **MedApps**

With respect to MedApps, the terms of the acquisition agreement require us to make earn-out payments upon achievement of certain technological and product development milestones through January 15, 2015. A portion of the earn-out, totaling \$3.0 million, was earned and paid during the second quarter of 2013. The maximum remaining amount of the earn-out payments is \$18.2 million.

NationsHealth

With respect to NationsHealth, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain operational targets within one year of the acquisition date. During the second quarter of 2013, the earn-out was accrued for a settlement amount of \$2.0 million, which will be paid during the third quarter of 2013. No further contingent consideration obligations related to this acquisition exist as of June 30, 2013.

ROAR

With respect to Forensics Limited, or ROAR, the terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain EBITDA targets during 2012 through 2014. Payment of the 2012 earn-out totaling approximately £1.0 million (approximately \$1.5 million), which was previously accrued at December 31, 2012, was made during the first quarter of 2013. The maximum remaining amount of the earn-out payments is £9.5 million (approximately \$14.4 million at June 30, 2013).

## Table of Contents

### (17) Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position, results of operations, comprehensive income or cash flows upon adoption.

#### *Recently Adopted Standards*

Effective January 1, 2013, we adopted ASU No. 2012-02, *Intangibles – Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment*, or ASU 2012-02. ASU 2012-02 allows an entity the option to first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinite-lived intangible asset is impaired. If an entity concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. However, if an entity concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount. An entity also has the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. An entity will be able to resume performing the qualitative assessment in any subsequent period. The adoption of this standard is not expected to have an impact on our financial position, results of operations, comprehensive income or cash flows.

### (18) Equity Investments

We account for the results from our equity investments under the equity method of accounting in accordance with ASC 323, *Investments – Equity Method and Joint Ventures*, based on the percentage of our ownership interest in the business. Our equity investments primarily include the following:

#### (a) SPD

We have a 50/50 joint venture, called SPD, with P&G for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiology, diabetes and oral care fields. We recorded earnings of \$4.2 million and \$6.7 million during the three and six months ended June 30, 2013, respectively, and losses of \$3.3 million and \$6.1 million during the three and six months ended June 30, 2012, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying consolidated statements of operations, which represented our 50% share of SPD's net income or losses, as applicable, for the respective periods.

#### (b) TechLab

We own 49% of TechLab, Inc., or TechLab, a privately-held developer, manufacturer and distributor of rapid non-invasive intestinal diagnostics tests in the areas of intestinal inflammation, antibiotic-associated diarrhea and parasitology. We recorded earnings of \$0.5 million and \$0.8 million during the three and six months ended June 30, 2013, respectively, and earnings of \$0.5 million and \$1.2 million during the three and six months ended June 30, 2012, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying consolidated statements of operations, which represented our minority share of TechLab's net income for the respective periods.

Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands):

Combined Condensed Results of Operations:	Three Months Ended June 30,		Six Months Ended June 30,	
	2013	2012	2013	2012
Net revenue	\$ 54,669	\$ 58,308	\$ 103,824	\$ 110,833
Gross profit	\$ 35,591	\$ 35,585	\$ 72,704	\$ 70,764
Net income after taxes	\$ 9,429	\$ 7,691	\$ 15,006	\$ 14,684

Edgar Filing: ALERE INC. - Form 10-Q

<b>Combined Condensed Balance Sheet:</b>	<b>June 30, 2013</b>	<b>December 31, 2012</b>
Current assets	\$ 80,378	\$ 79,842
Non-current assets	37,211	38,991
<b>Total assets</b>	<b>\$ 117,589</b>	<b>\$ 118,833</b>
Current liabilities	\$ 36,842	\$ 45,084
Non-current liabilities	6,261	6,791
<b>Total liabilities</b>	<b>\$ 43,103</b>	<b>\$ 51,875</b>

**Table of Contents**

**(19) Guarantor Financial Information**

Our 7.25% senior notes due 2018, our 8.625% senior subordinated notes due 2018, and our 6.5% senior subordinated notes due 2020 are guaranteed by certain of our consolidated wholly owned subsidiaries, or the Guarantor Subsidiaries. The guarantees are full and unconditional and joint and several. The following supplemental financial information sets forth, on a consolidating basis, balance sheets as of June 30, 2013 and December 31, 2012, the related statements of operations and statements of comprehensive income (loss) for each of the three and six months ended June 30, 2013 and 2012, respectively, and the statements of cash flows for the six months ended June 30, 2013 and 2012, for Alere Inc., the Guarantor Subsidiaries and our other subsidiaries, or the Non-Guarantor Subsidiaries. The supplemental financial information reflects the investments of Alere Inc. and the Guarantor Subsidiaries in the Guarantor and Non-Guarantor Subsidiaries using the equity method of accounting.

We have extensive transactions and relationships between various members of the consolidated group. These transactions and relationships include intercompany pricing agreements, intellectual property royalty agreements and general and administrative and research and development cost-sharing agreements. Because of these relationships, it is possible that the terms of these transactions are not the same as those that would result from transactions among wholly unrelated parties.

For comparative purposes, certain amounts for prior periods have been reclassified to conform to the current period classification.

**Table of Contents****CONSOLIDATING STATEMENT OF OPERATIONS****For the Three Months Ended June 30, 2013**

(in thousands)

	<b>Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations</b>	<b>Consolidated</b>
Net product sales	\$	\$ 208,925	\$ 365,328	\$ (52,691)	\$ 521,562
Services revenue		218,150	19,408		237,558
Net product sales and services revenue		427,075	384,736	(52,691)	759,120
License and royalty revenue		2,770	5,072	(2,977)	4,865
<b>Net revenue</b>		<b>429,845</b>	<b>389,808</b>	<b>(55,668)</b>	<b>763,985</b>
Cost of net product sales	887	117,550	180,947	(46,195)	253,189
Cost of services revenue		120,287	9,717	(5,194)	124,810
Cost of net product sales and services revenue	887	237,837	190,664	(51,389)	377,999
Cost of license and royalty revenue		18	4,458	(2,977)	1,499
<b>Cost of net revenue</b>	<b>887</b>	<b>237,855</b>	<b>195,122</b>	<b>(54,366)</b>	<b>379,498</b>
<b>Gross profit (loss)</b>	<b>(887)</b>	<b>191,990</b>	<b>194,686</b>	<b>(1,302)</b>	<b>384,487</b>
Operating expenses:					
Research and development	6,229	16,157	18,114		40,500
Sales and marketing	1,413	81,203	76,806		159,422
General and administrative	14,477	74,174	51,510		140,161
Total operating expenses	22,119	171,534	146,430		340,083
<b>Operating income (loss)</b>	<b>(23,006)</b>	<b>20,456</b>	<b>48,256</b>	<b>(1,302)</b>	<b>44,404</b>
Interest expense, including amortization of original issue discounts and deferred financing costs	(91,660)	(6,382)	(3,071)	8,660	(92,453)
Other income (expense), net	(5,607)	5,636	9,695	(8,661)	1,063
<b>Income (loss) before provision (benefit) for income taxes</b>	<b>(120,273)</b>	<b>19,710</b>	<b>54,880</b>	<b>(1,303)</b>	<b>(46,986)</b>
Provision (benefit) for income taxes	(10,360)	12,042	16,750	(565)	17,867
<b>Income (loss) before equity earnings (losses) of subsidiaries and unconsolidated entities, net of tax</b>	<b>(109,913)</b>	<b>7,668</b>	<b>38,130</b>	<b>(738)</b>	<b>(64,853)</b>
Equity earnings (losses) of subsidiaries, net of tax	49,045	(559)		(48,486)	
Equity earnings of unconsolidated entities, net of tax	566		4,027	(42)	4,551
<b>Net income (loss)</b>	<b>(60,302)</b>	<b>7,109</b>	<b>42,157</b>	<b>(49,266)</b>	<b>(60,302)</b>
Less: Net income attributable to non-controlling interests			267		267
<b>Net income (loss) attributable to Alere Inc. and Subsidiaries</b>	<b>(60,302)</b>	<b>7,109</b>	<b>41,890</b>	<b>(49,266)</b>	<b>(60,569)</b>
Preferred stock dividends	(5,309)				(5,309)

Edgar Filing: ALERE INC. - Form 10-Q

<b>Net income (loss) available to common stockholders</b>	\$ (65,611)	\$ 7,109	\$ 41,890	\$ (49,266)	\$ (65,878)
---	-------------	----------	-----------	-------------	-------------



**Table of Contents****CONSOLIDATING STATEMENT OF OPERATIONS****For the Three Months Ended June 30, 2012**

(in thousands)

	<b>Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations</b>	<b>Consolidated</b>
Net product sales	\$	\$ 206,818	\$ 286,145	\$ (29,538)	\$ 463,425
Services revenue		217,717	16,138		233,855
Net product sales and services revenue		424,535	302,283	(29,538)	697,280
License and royalty revenue		9,590	2,602	(8,955)	3,237
<b>Net revenue</b>		<b>434,125</b>	<b>304,885</b>	<b>(38,493)</b>	<b>700,517</b>
Cost of net product sales	857	98,110	152,555	(29,024)	222,498
Cost of services revenue		112,863	7,696		120,559
Cost of net product sales and services revenue	857	210,973	160,251	(29,024)	343,057
Cost of license and royalty revenue		5	10,802	(8,955)	1,852
<b>Cost of net revenue</b>	<b>857</b>	<b>210,978</b>	<b>171,053</b>	<b>(37,979)</b>	<b>344,909</b>
<b>Gross profit (loss)</b>	<b>(857)</b>	<b>223,147</b>	<b>133,832</b>	<b>(514)</b>	<b>355,608</b>
Operating expenses:					
Research and development	5,873	18,039	16,535		40,447
Sales and marketing	819	88,080	70,423		159,322
General and administrative	14,567	61,291	45,627		121,485
Total operating expenses	21,259	167,410	132,585		321,254
<b>Operating income (loss)</b>	<b>(22,116)</b>	<b>55,737</b>	<b>1,247</b>	<b>(514)</b>	<b>34,354</b>
Interest expense, including amortization of original issue discounts and deferred financing costs	(53,969)	(10,946)	(3,816)	13,200	(55,531)
Other income (expense), net	3,988	15,803	(2,780)	(13,200)	3,811
<b>Income (loss) before provision (benefit) for income taxes</b>	<b>(72,097)</b>	<b>60,594</b>	<b>(5,349)</b>	<b>(514)</b>	<b>(17,366)</b>
Provision (benefit) for income taxes	(19,750)	25,217	(5,839)	(117)	(489)
<b>Income (loss) before equity earnings (losses) of subsidiaries and unconsolidated entities, net of tax</b>	<b>(52,347)</b>	<b>35,377</b>	<b>490</b>	<b>(397)</b>	<b>(16,877)</b>
Equity earnings (losses) of subsidiaries, net of tax	38,982	(185)		(38,797)	
Equity earnings of unconsolidated entities, net of tax	486		3,502	10	3,998
<b>Net income (loss)</b>	<b>(12,879)</b>	<b>35,192</b>	<b>3,992</b>	<b>(39,184)</b>	<b>(12,879)</b>
Less: Net income attributable to non-controlling interests			36		36
<b>Net income (loss) attributable to Alere Inc. and Subsidiaries</b>	<b>(12,879)</b>	<b>35,192</b>	<b>3,956</b>	<b>(39,184)</b>	<b>(12,915)</b>
Preferred stock dividends	(5,279)				(5,279)

Edgar Filing: ALERE INC. - Form 10-Q

<b>Net income (loss) available to common stockholders</b>	\$ (18,158)	\$ 35,192	\$ 3,956	\$ (39,184)	\$ (18,194)
---	-------------	-----------	----------	-------------	-------------

**Table of Contents****CONSOLIDATING STATEMENT OF OPERATIONS**

For the Six Months Ended June 30, 2013

(in thousands)

	Issuer	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Eliminations	Consolidated
Net product sales	\$	\$ 442,418	\$ 686,225	\$ (98,805)	\$ 1,029,838
Services revenue		424,321	40,146		464,467
Net product sales and services revenue		866,739	726,371	(98,805)	1,494,305
License and royalty revenue		5,805	8,605	(5,481)	8,929
<b>Net revenue</b>		<b>872,544</b>	<b>734,976</b>	<b>(104,286)</b>	<b>1,503,234</b>
Cost of net product sales	1,835	238,144	354,163	(87,875)	506,267
Cost of services revenue		235,898	18,219	(9,149)	244,968
Cost of net product sales and services revenue	1,835	474,042	372,382	(97,024)	751,235
Cost of license and royalty revenue		35	8,701	(5,481)	3,255
<b>Cost of net revenue</b>	<b>1,835</b>	<b>474,077</b>	<b>381,083</b>	<b>(102,505)</b>	<b>754,490</b>
<b>Gross profit (loss)</b>	<b>(1,835)</b>	<b>398,467</b>	<b>353,893</b>	<b>(1,781)</b>	<b>748,744</b>
Operating expenses:					
Research and development	10,652	33,537	37,765		81,954
Sales and marketing	2,805	164,041	149,032		315,878
General and administrative	28,504	139,157	108,358		276,019
Total operating expenses	41,961	336,735	295,155		673,851
<b>Operating income (loss)</b>	<b>(43,796)</b>	<b>61,732</b>	<b>58,738</b>	<b>(1,781)</b>	<b>74,893</b>
Interest expense, including amortization of original issue discounts and deferred financing costs	(148,518)	(13,403)	(6,488)	18,557	(149,852)
Other income (expense), net	(837)	11,895	8,092	(18,557)	593
<b>Income (loss) before provision (benefit) for income taxes</b>	<b>(193,151)</b>	<b>60,224</b>	<b>60,342</b>	<b>(1,781)</b>	<b>(74,366)</b>
Provision (benefit) for income taxes	(73,171)	29,968	24,877	(678)	(19,004)
<b>Income (loss) before equity earnings (losses) of subsidiaries and unconsolidated entities, net of tax</b>	<b>(119,980)</b>	<b>30,256</b>	<b>35,465</b>	<b>(1,103)</b>	<b>(55,362)</b>
Equity earnings (losses) of subsidiaries, net of tax	71,289	(1,173)		(70,116)	
Equity earnings of unconsolidated entities, net of tax	814		6,715	(44)	7,485
<b>Net income (loss)</b>	<b>(47,877)</b>	<b>29,083</b>	<b>42,180</b>	<b>(71,263)</b>	<b>(47,877)</b>
Less: Net income attributable to non-controlling interests			242		242
<b>Net income (loss) attributable to Alere Inc. and Subsidiaries</b>	<b>(47,877)</b>	<b>29,083</b>	<b>41,938</b>	<b>(71,263)</b>	<b>(48,119)</b>
Preferred stock dividends	(10,559)				(10,559)

Edgar Filing: ALERE INC. - Form 10-Q

<b>Net income (loss) available to common stockholders</b>	\$ (58,436)	\$ 29,083	\$ 41,938	\$ (71,263)	\$ (58,678)
---	-------------	-----------	-----------	-------------	-------------

**Table of Contents****CONSOLIDATING STATEMENT OF OPERATIONS****For the Six Months Ended June 30, 2012**

(in thousands)

	<b>Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations</b>	<b>Consolidated</b>
Net product sales	\$	\$ 430,235	\$ 571,744	\$ (62,767)	\$ 939,212
Services revenue		394,432	31,857		426,289
Net product sales and services revenue		824,667	603,601	(62,767)	1,365,501
License and royalty revenue		13,894	5,148	(12,897)	6,145
<b>Net revenue</b>		<b>838,561</b>	<b>608,749</b>	<b>(75,664)</b>	<b>1,371,646</b>
Cost of net product sales	1,707	204,312	304,153	(62,120)	448,052
Cost of services revenue		196,506	14,913		211,419
Cost of net product sales and services revenue	1,707	400,818	319,066	(62,120)	659,471
Cost of license and royalty revenue		10	16,383	(12,897)	3,496
<b>Cost of net revenue</b>	<b>1,707</b>	<b>400,828</b>	<b>335,449</b>	<b>(75,017)</b>	<b>662,967</b>
<b>Gross profit (loss)</b>	<b>(1,707)</b>	<b>437,733</b>	<b>273,300</b>	<b>(647)</b>	<b>708,679</b>
Operating expenses:					
Research and development	11,069	35,521	32,857		79,447
Sales and marketing	1,876	174,417	141,607		317,900
General and administrative	26,198	125,935	89,787		241,920
Total operating expenses	39,143	335,873	264,251		639,267
<b>Operating income (loss)</b>	<b>(40,850)</b>	<b>101,860</b>	<b>9,049</b>	<b>(647)</b>	<b>69,412</b>
Interest expense, including amortization of original issue discounts and deferred financing costs	(103,685)	(22,013)	(7,070)	26,510	(106,258)
Other income (expense), net	(4,086)	25,231	21,007	(26,510)	15,642
<b>Income (loss) before provision (benefit) for income taxes</b>	<b>(148,621)</b>	<b>105,078</b>	<b>22,986</b>	<b>(647)</b>	<b>(21,204)</b>
Provision (benefit) for income taxes	(46,748)	41,999	2,851	(46)	(1,944)
<b>Income (loss) before equity earnings (losses) of subsidiaries and unconsolidated entities, net of tax</b>	<b>(101,873)</b>	<b>63,079</b>	<b>20,135</b>	<b>(601)</b>	<b>(19,260)</b>
Equity earnings (losses) of subsidiaries, net of tax	88,877	(533)		(88,344)	
Equity earnings of unconsolidated entities, net of tax	1,146		6,238	26	7,410
<b>Net income (loss)</b>	<b>(11,850)</b>	<b>62,546</b>	<b>26,373</b>	<b>(88,919)</b>	<b>(11,850)</b>
Less: Net loss attributable to non-controlling interests			(149)		(149)
<b>Net income (loss) attributable to Alere Inc. and Subsidiaries</b>	<b>(11,850)</b>	<b>62,546</b>	<b>26,522</b>	<b>(88,919)</b>	<b>(11,701)</b>
Preferred stock dividends	(10,588)				(10,588)

Edgar Filing: ALERE INC. - Form 10-Q

<b>Net income (loss) available to common stockholders</b>	\$ (22,438)	\$ 62,546	\$ 26,522	\$ (88,919)	\$ (22,289)
---	-------------	-----------	-----------	-------------	-------------

**Table of Contents****CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS)****For the Three Months Ended June 30, 2013**

(in thousands)

	<b>Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations</b>	<b>Consolidated</b>
Net income (loss)	\$ (60,302)	\$ 7,109	\$ 42,157	\$ (49,266)	\$ (60,302)
Other comprehensive loss, before tax:					
Changes in cumulative translation adjustment	(652)		(33,776)		(34,428)
Minimum pension liability adjustment			99		99
Other comprehensive loss, before tax	(652)		(33,677)		(34,329)
Income tax provision (benefit) related to items of other comprehensive income					
Other comprehensive loss, net of tax	(652)		(33,677)		(34,329)
Comprehensive income (loss)	(60,954)	7,109	8,480	(49,266)	(94,631)
Less: Comprehensive income attributable to non-controlling interests			267		267
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	\$ (60,954)	\$ 7,109	\$ 8,213	\$ (49,266)	\$ (94,898)

**Table of Contents****CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS)****For the Three Months Ended June 30, 2012**

(in thousands)

	<b>Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations</b>	<b>Consolidated</b>
Net income (loss)	\$ (12,879)	\$ 35,192	\$ 3,992	\$ (39,184)	\$ (12,879)
Other comprehensive income (loss), before tax:					
Changes in cumulative translation adjustment	(562)	4	(34,142)	(2,077)	(36,777)
Unrealized gains on available for sale securities	356	3			359
Unrealized losses on hedging instruments			(652)		(652)
Minimum pension liability adjustment			4		4
Other comprehensive income (loss), before tax	(206)	7	(34,790)	(2,077)	(37,066)
Income tax provision (benefit) related to items of other comprehensive income					
Other comprehensive income (loss), net of tax	(206)	7	(34,790)	(2,077)	(37,066)
Comprehensive income (loss)	(13,085)	35,199	(30,798)	(41,261)	(49,945)
Less: Comprehensive income attributable to non-controlling interests			36		36
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	\$ (13,085)	\$ 35,199	\$ (30,834)	\$ (41,261)	\$ (49,981)



**Table of Contents****CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS)****For the Six Months Ended June 30, 2013**

(in thousands)

	<b>Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations</b>	<b>Consolidated</b>
Net income (loss)	\$ (47,877)	\$ 29,083	\$ 42,180	\$ (71,263)	\$ (47,877)
Other comprehensive loss, before tax:					
Changes in cumulative translation adjustment	(853)		(108,930)		(109,783)
Unrealized gains on hedging instruments			11		11
Minimum pension liability adjustment			704		704
Other comprehensive loss, before tax	(853)		(108,215)		(109,068)
Income tax provision (benefit) related to items of other comprehensive income					
Other comprehensive loss, net of tax	(853)		(108,215)		(109,068)
Comprehensive income (loss)	(48,730)	29,083	(66,035)	(71,263)	(156,945)
Less: Comprehensive income attributable to non-controlling interests			242		242
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	\$ (48,730)	\$ 29,083	\$ (66,277)	\$ (71,263)	\$ (157,187)

**Table of Contents****CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS)****For the Six Months Ended June 30, 2012**

(in thousands)

	<b>Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations</b>	<b>Consolidated</b>
Net income (loss)	\$ (11,850)	\$ 62,546	\$ 26,373	\$ (88,919)	\$ (11,850)
Other comprehensive income (loss), before tax:					
Changes in cumulative translation adjustment	(233)	(302)	1,109	(1,412)	(838)
Unrealized gains on available for sale securities	785	5			790
Unrealized gains on hedging instruments	17		438		455
Minimum pension liability adjustment			(120)		(120)
Other comprehensive income (loss), before tax	569	(297)	1,427	(1,412)	287
Income tax provision (benefit) related to items of other comprehensive income					
Other comprehensive income (loss), net of tax	569	(297)	1,427	(1,412)	287
Comprehensive income (loss)	(11,281)	62,249	27,800	(90,331)	(11,563)
Less: Comprehensive loss attributable to non-controlling interests			(149)		(149)
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	\$ (11,281)	\$ 62,249	\$ 27,949	\$ (90,331)	\$ (11,414)

**Table of Contents****CONSOLIDATING BALANCE SHEET****June 30, 2013**

(in thousands)

	<b>Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations</b>	<b>Consolidated</b>
<b>ASSETS</b>					
<b>Current assets:</b>					
Cash and cash equivalents	\$ 3,467	\$ 64,192	\$ 252,888	\$	\$ 320,547
Restricted cash	6,248	2,309	1,362		9,919
Marketable securities		779	110		889
Accounts receivable, net of allowances		233,549	320,211		553,760
Inventories, net		163,592	217,256	(24,095)	356,753
Deferred tax assets	10,418	37,369	9,614	3,448	60,849
Prepaid expenses and other current assets	3,945	33,942	68,509	(36)	106,360
Intercompany receivables	322,759	650,991	58,348	(1,032,098)	
<b>Total current assets</b>	<b>346,837</b>	<b>1,186,723</b>	<b>928,298</b>	<b>(1,052,781)</b>	<b>1,409,077</b>
Property, plant and equipment, net	2,638	290,341	237,944	(456)	530,467
Goodwill		1,811,304	1,284,494		3,095,798
Other intangible assets with indefinite lives		12,900	44,446		57,346
Finite-lived intangible assets, net	9,672	1,047,346	754,933		1,811,951
Deferred financing costs, net and other non-current assets	61,992	10,261	17,192	(62)	89,383
Investments in subsidiaries	4,359,116	279,981	3,562	(4,642,659)	
Investments in unconsolidated entities	30,201		52,345	13,651	96,197
Deferred tax assets			9,786		9,786
Intercompany notes receivable	1,632,819	747,564	58,687	(2,439,070)	
<b>Total assets</b>	<b>\$ 6,443,275</b>	<b>\$ 5,386,420</b>	<b>\$ 3,391,687</b>	<b>\$ (8,121,377)</b>	<b>\$ 7,100,005</b>
<b>LIABILITIES AND EQUITY</b>					
<b>Current liabilities:</b>					
Current portion of long-term debt	\$ 45,000	\$ 626	\$ 4,913	\$	\$ 50,539
Current portion of capital lease obligations		3,187	2,771		5,958
Accounts payable	8,848	75,709	93,995		178,552
Accrued expenses and other current liabilities	(387,789)	581,594	232,155	(581)	425,379
Intercompany payables	628,617	133,465	270,014	(1,032,096)	
<b>Total current liabilities</b>	<b>294,676</b>	<b>794,581</b>	<b>603,848</b>	<b>(1,032,677)</b>	<b>660,428</b>
<b>Long-term liabilities:</b>					
Long-term debt, net of current portion	3,792,478	224	15,600		3,808,302
Capital lease obligations, net of current portion		4,743	6,942		11,685
Deferred tax liabilities	(18,036)	301,061	106,542	445	390,012
Other long-term liabilities	17,972	58,061	121,810	(62)	197,781
Intercompany notes payables	328,613	1,591,479	518,978	(2,439,070)	
<b>Total long-term liabilities</b>	<b>4,121,027</b>	<b>1,955,568</b>	<b>769,872</b>	<b>(2,438,687)</b>	<b>4,407,780</b>
<b>Stockholders equity</b>	<b>2,027,572</b>	<b>2,636,271</b>	<b>2,013,742</b>	<b>(4,650,013)</b>	<b>2,027,572</b>
Non-controlling interests			4,225		4,225

Edgar Filing: ALERE INC. - Form 10-Q

<b>Total equity</b>	2,027,572	2,636,271	2,017,967	(4,650,013)	2,031,797
<b>Total liabilities and equity</b>	\$ 6,443,275	\$ 5,386,420	\$ 3,391,687	\$ (8,121,377)	\$ 7,100,005

**Table of Contents****CONSOLIDATING BALANCE SHEET**

December 31, 2012

(in thousands)

	Issuer	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Eliminations	Consolidated
<b>ASSETS</b>					
<b>Current assets:</b>					
Cash and cash equivalents	\$ 3,623	\$ 67,449	\$ 257,274	\$	\$ 328,346
Restricted cash		1,680	1,396		3,076
Marketable securities		787	117		904
Accounts receivable, net of allowances		241,050	283,282		524,332
Inventories, net		142,413	203,230	(8,522)	337,121
Deferred tax assets	12,193	39,601	13,138	2,790	67,722
Prepaid expenses and other current assets	(20,636)	99,271	66,634	(33)	145,236
Intercompany receivables	298,812	1,254,727	55,847	(1,609,386)	
<b>Total current assets</b>	<b>293,992</b>	<b>1,846,978</b>	<b>880,918</b>	<b>(1,615,151)</b>	<b>1,406,737</b>
Property, plant and equipment, net	2,679	293,260	239,082	(552)	534,469
Goodwill		1,820,438	1,227,967		3,048,405
Other intangible assets with indefinite lives		14,600	21,851		36,451
Finite-lived intangible assets, net	24,701	1,132,656	676,868		1,834,225
Deferred financing costs, net and other non-current assets	78,522	10,341	20,065	(71)	108,857
Investments in subsidiaries	4,114,478	222,175	73,940	(4,410,593)	
Investments in unconsolidated entities	33,979		56,512		90,491
Deferred tax assets		782	7,511		8,293
Intercompany notes receivable	1,724,650	722,552	1,278	(2,448,480)	
<b>Total assets</b>	<b>\$ 6,273,001</b>	<b>\$ 6,063,782</b>	<b>\$ 3,205,992</b>	<b>\$ (8,474,847)</b>	<b>\$ 7,067,928</b>
<b>LIABILITIES AND EQUITY</b>					
<b>Current liabilities:</b>					
Current portion of long-term debt	\$ 45,000	\$ 349	\$ 14,883	\$	\$ 60,232
Current portion of capital lease obligations		3,209	3,475		6,684
Accounts payable	7,993	76,256	85,725		169,974
Accrued expenses and other current liabilities	(388,830)	586,116	214,659	(26)	411,919
Intercompany payables	557,578	806,507	245,300	(1,609,385)	
<b>Total current liabilities</b>	<b>221,741</b>	<b>1,472,437</b>	<b>564,042</b>	<b>(1,609,411)</b>	<b>648,809</b>
<b>Long-term liabilities:</b>					
Long-term debt, net of current portion	3,617,068	374	11,233		3,628,675
Capital lease obligations, net of current portion		5,412	7,505		12,917
Deferred tax liabilities	(5,329)	333,388	100,216	(87)	428,188
Other long-term liabilities	17,678	72,890	76,138	(71)	166,635
Intercompany notes payables	241,421	1,630,376	576,684	(2,448,481)	
<b>Total long-term liabilities</b>	<b>3,870,838</b>	<b>2,042,440</b>	<b>771,776</b>	<b>(2,448,639)</b>	<b>4,236,415</b>
<b>Stockholders equity</b>	<b>2,180,422</b>	<b>2,548,905</b>	<b>1,867,892</b>	<b>(4,416,797)</b>	<b>2,180,422</b>
Non-controlling interests			2,282		2,282

Edgar Filing: ALERE INC. - Form 10-Q

<b>Total equity</b>	2,180,422	2,548,905	1,870,174	(4,416,797)	2,182,704
<b>Total liabilities and equity</b>	\$ 6,273,001	\$ 6,063,782	\$ 3,205,992	\$ (8,474,847)	\$ 7,067,928

**Table of Contents****CONSOLIDATING STATEMENT OF CASH FLOWS****For the Six Months Ended June 30, 2013**

(in thousands)

	<b>Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations</b>	<b>Consolidated</b>
<b>Cash Flows from Operating Activities:</b>					
Net income (loss)	\$ (47,877)	\$ 29,083	\$ 42,180	\$ (71,263)	\$ (47,877)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:					
Equity (earnings) losses of subsidiaries, net of tax	(71,289)	1,173		70,116	
Non-cash interest expense, including amortization of original issue discounts and write-off of deferred financing costs	10,041	117	18		10,176
Depreciation and amortization	2,499	124,375	87,042	(12)	213,904
Non-cash charges for sale of inventories revalued at the date of acquisition			1,172		1,172
Non-cash stock-based compensation expense	3,476	2,459	2,865		8,800
Impairment of inventory		26			26
Impairment of long-lived assets		2,815			2,815
Loss on sale of fixed assets		625	676		1,301
Equity earnings of unconsolidated entities, net of tax	(814)		(6,715)	44	(7,485)
Deferred income taxes	(9,994)	(24,534)	(8,902)	(622)	(44,052)
Loss on extinguishment of debt	35,603				35,603
Other non-cash items	5,202	(327)	(5,602)		(727)
Changes in assets and liabilities, net of acquisitions:					
Accounts receivable, net		7,502	(45,828)		(38,326)
Inventories, net		(33,342)	(20,640)	1,878	(52,104)
Prepaid expenses and other current assets	(64,581)	66,399	1,008	(6,145)	(3,319)
Accounts payable	855	1,397	9,598		11,850
Accrued expenses and other current liabilities	12,197	(7,377)	14,434	5,592	24,846
Other non-current liabilities	(1,890)	(10,891)	(5,569)	506	(17,844)
Intercompany payable (receivable)	160,040	(135,316)	(24,724)		
<b>Net cash provided by operating activities</b>	<b>33,468</b>	<b>24,184</b>	<b>41,013</b>	<b>94</b>	<b>98,759</b>
<b>Cash Flows from Investing Activities:</b>					
Increase in restricted cash	(6,170)	(630)	(43)		(6,843)
Purchases of property, plant and equipment	(277)	(29,543)	(40,775)	5,978	(64,617)
Proceeds from sale of property, plant and equipment		5,831	4,872	(6,063)	4,640
Cash paid for acquisitions, net of cash acquired	(157,372)		(8,591)		(165,963)
Cash received from equity method investments			10,574		10,574
(Increase) decrease in other assets	19,321	(1,650)	(649)	(9)	17,013
<b>Net cash used in investing activities</b>	<b>(144,498)</b>	<b>(25,992)</b>	<b>(34,612)</b>	<b>(94)</b>	<b>(205,196)</b>
<b>Cash Flows from Financing Activities:</b>					
Cash paid for financing costs	(9,018)				(9,018)
Cash paid for contingent purchase price consideration	(26,430)		(208)		(26,638)
Proceeds from issuance of common stock, net of issuance costs	7,772				7,772
Proceeds from issuance of long-term debt	425,000	1,019	9,448		435,467

Edgar Filing: ALERE INC. - Form 10-Q

Payments on long-term debt	(431,845)	(890)	(5,081)	(437,816)
Net proceeds (payments) under revolving credit facilities	175,000		(8,460)	166,540
Cash paid for dividends	(10,646)			(10,646)
Excess tax benefits on exercised stock options	72	39	55	166
Principal payments on capital lease obligations		(1,626)	(1,862)	(3,488)
Other	(18,953)			(18,953)
<b>Net cash provided by (used in) financing activities</b>	<b>110,952</b>	<b>(1,458)</b>	<b>(6,108)</b>	<b>103,386</b>
Foreign exchange effect on cash and cash equivalents	(78)	9	(4,679)	(4,748)
Net decrease in cash and cash equivalents	(156)	(3,257)	(4,386)	(7,799)
Cash and cash equivalents, beginning of period	3,623	67,449	257,274	328,346
<b>Cash and cash equivalents, end of period</b>	<b>\$ 3,467</b>	<b>\$ 64,192</b>	<b>\$ 252,888</b>	<b>\$ 320,547</b>



**Table of Contents****CONSOLIDATING STATEMENT OF CASH FLOWS****For the Six Months Ended June 30, 2012**

(in thousands)

	<b>Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations</b>	<b>Consolidated</b>
<b>Cash Flows from Operating Activities:</b>					
Net income (loss)	\$ (11,850)	\$ 62,546	\$ 26,373	\$ (88,919)	\$ (11,850)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:					
Equity (earnings) losses of subsidiaries, net of tax	(88,877)	533		88,344	
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs	10,568	110	53		10,731
Depreciation and amortization	3,195	130,725	77,656	46	211,622
Non-cash charges for sale of inventories revalued at the date of acquisition		1,400	3,281		4,681
Non-cash stock-based compensation expense	2,166	3,065	3,011		8,242
Impairment of inventory		5			5
Impairment of long-lived assets		219			219
(Gain) loss on sale of fixed assets		(5,900)	28		(5,872)
Equity earnings of unconsolidated entities, net of tax	(1,146)		(6,238)	(26)	(7,410)
Deferred income taxes	7,771	(25,088)	(10,037)	(46)	(27,400)
Other non-cash items	(883)				(883)
Changes in assets and liabilities, net of acquisitions:					
Accounts receivable, net		6,037	(11,468)		(5,431)
Inventories, net		2,783	(7,640)	445	(4,412)
Prepaid expenses and other current assets	(372,901)	391,876	(2,126)	17	16,866
Accounts payable	(786)	3,340	(16,801)		(14,247)
Accrued expenses and other current liabilities	327,975	(321,909)	(5,918)	(514)	(366)
Other non-current liabilities	(6,781)	(1,778)	(177)	471	(8,265)
Intercompany payable (receivable)	231,769	(249,211)	17,442		
<b>Net cash provided by (used in) operating activities</b>	<b>100,220</b>	<b>(1,247)</b>	<b>67,439</b>	<b>(182)</b>	<b>166,230</b>
<b>Cash Flows from Investing Activities:</b>					
Decrease in restricted cash		12	5,876		5,888
Purchases of property, plant and equipment	(1,028)	(40,545)	(28,788)	900	(69,461)
Proceeds from sale of property, plant and equipment		21,927	495	(745)	21,677
Cash received (paid) for acquisitions, net of cash acquired	(296,189)	1,469	(15,520)		(310,240)
Net cash received from equity method investments	490		6,066		6,556
Proceeds from sales of marketable securities		223	3		226
(Increase) decrease in other assets	(8,973)	2,054	(822)	27	(7,714)
<b>Net cash used in investing activities</b>	<b>(305,700)</b>	<b>(14,860)</b>	<b>(32,690)</b>	<b>182</b>	<b>(353,068)</b>
<b>Cash Flows from Financing Activities:</b>					
Cash paid for financing costs	(2,013)				(2,013)
Cash paid for contingent purchase price consideration	(6,500)				(6,500)
Proceeds from issuance of common stock, net of issuance costs	8,697				8,697
Proceeds from issuance of long-term debt	198,000	951	283		199,234
Payments on long-term debt	(22,000)	(1,090)	(6,794)		(29,884)

Edgar Filing: ALERE INC. - Form 10-Q

Net proceeds (payments) under revolving credit facilities	47,500	(2)	(5,011)	42,487
Payments on short-term debt	(6,240)			(6,240)
Cash paid for dividends	(10,646)			(10,646)
Excess tax benefits on exercised stock options	120	74	16	210
Principal payments on capital lease obligations		(881)	(2,438)	(3,319)
Other			(2,577)	(2,577)
<b>Net cash provided by (used in) financing activities</b>	<b>206,918</b>	<b>(948)</b>	<b>(16,521)</b>	<b>189,449</b>
Foreign exchange effect on cash and cash equivalents		(78)	2,033	1,955
Net increase (decrease) in cash and cash equivalents	1,438	(17,133)	20,261	4,566
Cash and cash equivalents, beginning of period	12,451	95,212	191,510	299,173
<b>Cash and cash equivalents, end of period</b>	<b>\$ 13,889</b>	<b>\$ 78,079</b>	<b>\$ 211,771</b>	<b>\$ 303,739</b>

---

**Table of Contents****ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS****Forward-Looking Statements**

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can identify these statements by forward-looking words such as may, could, should, would, intend, will, expect, anticipate, believe, estimate, continue or similar words. You should read statements that contain these words carefully because they discuss our future expectations, contain projections of our future results of operations or of our financial condition or state other forward-looking information. Forward-looking statements include, without limitation, statements regarding anticipated expansion and growth in certain of our product and service offerings, the impact of our research and development activities, potential new product and technology achievements, the potential for selective acquisitions, our ability to improve our working capital and operating margins, our expectations with respect to Apollo, our integrated health information solutions technology platform, our ability to improve care and lower healthcare costs for both providers and patients, the effect of the Affordable Care Act and other initiatives to reduce healthcare expenses, the potential for divestitures of non-core assets and the effects of any such divestitures, and our funding plans for our future working capital needs and commitments. Actual results or developments could differ materially from those projected in such statements as a result of numerous factors, including, without limitation, those risks and uncertainties set forth in Part I, Item 1A, Risk Factors, of our Annual Report on Form 10-K, as amended, for the year ended December 31, 2012 and other risk factors identified herein or from time to time in our periodic filings with the SEC. We do not undertake any obligation to update any forward-looking statements. This report and, in particular, the following discussion and analysis of our financial condition and results of operations should be read in light of those risks and uncertainties and in conjunction with our accompanying consolidated financial statements and notes thereto.

**Overview**

We enable individuals to take greater control of their health at home, under the supervision of their healthcare providers, by combining near-patient diagnostics, health monitoring capabilities and health information solutions. A leading global provider of point-of-care diagnostics and services, we have developed a strong commercial presence in cardiology, infectious disease, toxicology, and diabetes. Our products and services help healthcare practitioners make earlier, more effective treatment decisions and improve outcomes for individuals living with chronic disease.

During 2012, we focused on completing the foundation for this business model by expanding our presence in toxicology and diabetes through acquisitions. Our toxicology group is now a full-service provider to a broad range of domestic and foreign employers in industries that require rigorous drug testing. We built a strong presence in diabetes from the ground up. Including the effect of acquisitions completed in early 2013, we now service more than 455,000 active diabetes customers. We believe that the strong foundation that we have built in diabetes, specifically in our mail-order diabetes testing supply business, provides us with a competitive advantage in dealing with the impact that Centers for Medicare and Medicaid Services, or CMS, competitive bidding program, which resulted in an approximately 70% reduction in reimbursement rates effective as of July 1, 2013, is projected to have on competition and pricing in the market for diabetes testing supplies.

Core to our strategy are health information solutions that enable diagnostic data to be fed directly into an information exchange that integrates the diagnostic data with other patient-related information in a single health record. In recent periods, we have focused on acquiring health information solutions that will supplement our internally developed information solutions, including Apollo, and improve our ability to execute our business strategy. We now offer a variety of connectivity tools, software-based analytics, clinical decision support tools, and health improvement programs that enable healthcare providers to initiate earlier interventions, personalize treatment plans, lower costs by reducing hospital readmissions, and measure improvements in outcomes at both a patient and population level.

We also continue to build momentum behind our next generation of novel diagnostic platforms that we expect will drive our growth in future years. With our novel molecular diagnostic platforms in the late stages of development and nearing launch, we have now begun to refocus our research and development efforts away from long-term projects towards product enhancements and menu expansion for our existing and recently launched platforms.

We are also focused on improving our operational efficiency, including reducing selling, general and administrative expense, in order to generate dependable, long-term cash flow. Additionally, with the foundation of our business essentially complete, we expect to consider divesting of non-core businesses. We expect to use our improved cash flow, as well as the proceeds from non-core divestitures, or portions thereof, to reduce our indebtedness without compromising our core businesses.

**Financial Highlights**

## Edgar Filing: ALERE INC. - Form 10-Q

Net revenue increased by \$63.5 million, or 9%, to \$764.0 million for the three months ended June 30, 2013, from \$700.5 million for the three months ended June 30, 2012. Net revenue increased by \$131.6 million, or 10%, to \$1.5 billion for the six months ended June 30, 2013, from \$1.4 billion for the six months ended June 30, 2012.

Gross profit increased by \$28.9 million, or 8%, to \$384.5 million for the three months ended June 30, 2013, from \$355.6 million for the three months ended June 30, 2012. Gross profit increased by \$40.1 million, or 6%, to \$748.7 million for the six months ended June 30, 2013, from \$708.7 million for the six months ended June 30, 2012.

**Table of Contents**

For the three months ended June 30, 2013, we generated a net loss available to common stockholders of \$65.9 million, or \$0.81 per diluted common share, compared to a net loss available to common stockholders of \$18.2 million, or \$0.23 per diluted common share, for the three months ended June 30, 2012. For the six months ended June 30, 2013, we generated a net loss available to common stockholders of \$58.7 million, or \$0.72 per diluted common share, compared to a net loss available to common stockholders of \$22.3 million, or \$0.28 per diluted common share, for the six months ended June 30, 2012.

Net loss for the three and six months ended June 30, 2013 includes a \$35.6 million loss on extinguishment of debt in connection with the repurchase of our 9% senior subordinated notes.

**Results of Operations**

Where discussed, results excluding the impact of foreign currency translation are calculated on the basis of local currency results, using foreign currency exchange rates applicable to the earlier comparative period. We believe presenting information using the same foreign currency exchange rates helps investors isolate the impact of changes in those rates from other trends. Our results of operations were as follows:

**Net Product Sales and Services Revenue, Total and by Business Segment.** Total net product sales and services revenue increased by \$61.8 million, or 9%, to \$759.1 million for the three months ended June 30, 2013, from \$697.3 million for the three months ended June 30, 2012. Excluding the impact of currency translation, net product sales and services revenue for the three months ended June 30, 2013 increased by \$65.4 million, or 9%, compared to the three months ended June 30, 2012. Total net product sales and services revenue increased by \$128.8 million, or 9%, to \$1.5 billion for the six months ended June 30, 2013, from \$1.4 billion for the six months ended June 30, 2012. Excluding the impact of currency translation, net product sales and services revenue for the six months ended June 30, 2013 increased by \$135.7 million, or 10%, compared to the six months ended June 30, 2012. Net product sales and services revenue by business segment for the three and six months ended June 30, 2013 and 2012 are as follows (in thousands):

	Three Months Ended June 30,		%	Six Months Ended June 30,		%
	2013	2012	Change	2013	2012	Change
Professional diagnostics	\$ 599,597	\$ 536,873	12%	\$ 1,178,225	\$ 1,052,322	12%
Health information solutions	134,775	138,590	(3)%	268,982	269,374	%
Consumer diagnostics	24,748	21,817	13%	47,098	43,805	8%
Net product sales and services revenue	\$ 759,120	\$ 697,280	9%	\$ 1,494,305	\$ 1,365,501	9%

*Professional Diagnostics*

The following table summarizes our net product sales and services revenue from our professional diagnostics business segment by groups of similar products and services for the three and six months ended June 30, 2013 and 2012 (in thousands):

	Three Months Ended June 30		%	Six Months Ended June 30,		%
	2013	2012	Change	2013	2012	Change
Cardiology	\$ 118,436	\$ 125,597	(6)%	\$ 233,369	\$ 264,423	(12)%
Infectious disease	157,706	137,821	14%	347,550	288,837	20%
Toxicology	165,884	159,922	4%	314,933	281,662	12%
Diabetes	74,905	36,797	104%	124,988	64,958	92%
Other	82,666	76,736	8%	157,385	152,442	3%
Professional diagnostics net product sales and services revenue	\$ 599,597	\$ 536,873	12%	\$ 1,178,225	\$ 1,052,322	12%

Net product sales and services revenue from our professional diagnostics business segment increased by \$62.7 million, or 12%, to \$599.6 million for the three months ended June 30, 2013, from \$536.9 million for the three months ended June 30, 2012. Excluding the impact of currency translation, net product sales and services revenue from our professional diagnostics business segment increased by \$66.7 million, or

## Edgar Filing: ALERE INC. - Form 10-Q

12%, comparing the three months ended June 30, 2013 to the three months ended June 30, 2012. Revenue increased primarily as a result of acquisitions, which contributed an aggregate of \$47.4 million of the non-currency-adjusted increase. Offsetting the increase in net product sales and services revenue was a decrease in our North American flu-related net product sales during the three months ended June 30, 2013, as compared to the three months ended June 30, 2012. Net product sales from our North American flu-related sales decreased approximately \$2.2 million, from \$4.2 million during the three months ended June 30, 2012 to \$2.0 million during the three months ended June 30, 2013. Net product sales and services revenue from our professional diagnostics business segment were negatively impacted by the FDA matters related to our Alere Triage® meter-based products. Net product sales of meter-based Triage products in the U.S. totaled \$19.3 million during the three months ended June 30, 2013, as compared to \$40.6 million during the three months ended June 30, 2012. Excluding the impact of acquisitions, the

**Table of Contents**

decrease in flu-related sales during the comparable periods and the impact of the reduction in net product sales from meter-based Triage products in the U.S., the currency-adjusted organic growth for our professional diagnostics net product sales and services revenue was approximately \$42.8 million, or 9%, from the three months ended June 30, 2012 to the three months ended June 30, 2013.

Within our professional diagnostics business segment, net product sales and services revenue for our cardiology business decreased by approximately \$7.2 million, or 6%, to \$118.4 million for the three months ended June 30, 2013, from \$125.6 million for the three months ended June 30, 2012, driven principally by the impact of the FDA review of certain of our meter-based Triage products in the U.S. Net product sales and services revenue for our infectious disease business increased by approximately \$19.9 million, or 14%, to \$157.7 million for the three months ended June 30, 2013, from \$137.8 million for the three months ended June 30, 2012. The change was driven principally by an increase in malaria-related sales during the comparable periods. Net product sales and services revenue for our toxicology business increased by approximately \$6.0 million, or 4%, to \$165.9 million for the three months ended June 30, 2013, from \$159.9 million for the three months ended June 30, 2012, with our recent acquisitions of eScreen, Inc., or eScreen, Amedica Biotech, Inc., or Amedica, and Branan Medical Corporation, or Branan, contributing a combined net \$6.3 million of the non-currency adjusted increase. Offsetting the increase in net product sales and services revenue for our toxicology business contributed by acquisitions was a \$7.4 million decrease in net product sales related to our Triage toxicology products. Net product sales and services revenue from our diabetes business increased by approximately \$38.1 million, or 104%, to \$74.9 million for the three months ended June 30, 2013, from \$36.8 million for the three months ended June 30, 2012. Net product sales and services revenue from our diabetes business increased by approximately \$38.1 million, or 104%, to \$74.9 million for the three months ended June 30, 2013, from \$36.8 million for the three months ended June 30, 2012. The increase was primarily the result of our recent acquisitions of NationsHealth, Discount Diabetics and the Liberty business, which contributed a combined net \$36.3 million of the non-currency adjusted increase. Notwithstanding the growth in our diabetes business, in light of CMS reduced reimbursement rates for diabetes testing supplies that took effect in July 2013, we expect that revenues from our diabetes business will decline substantially in the third quarter of 2013.

Net product sales and services revenue from our professional diagnostics business segment increased by \$125.9 million, or 12%, to \$1.2 billion for the six months ended June 30, 2013, from \$1.1 billion for the six months ended June 30, 2012. Excluding the impact of currency translation, net product sales and services revenue from our professional diagnostics business segment increased by \$135.7 million, or 10%, comparing the six months ended June 30, 2013 to the six months ended June 30, 2012. Revenue increased primarily as a result of acquisitions, which contributed an aggregate of \$109.4 million of the non-currency-adjusted increase. Contributing to the increase in net product sales and services revenue was an increase in our North American flu-related net product sales during the six months ended June 30, 2013, as compared to the six months ended June 30, 2012. Net product sales from our North American flu-related sales increased approximately \$25.6 million, from \$10.8 million during the six months ended June 30, 2012 to \$36.3 million during the six months ended June 30, 2013. Net product sales and services revenue from our professional diagnostics business segment were negatively impacted by the FDA matters related to our Alere Triage<sup>®</sup> meter-based products. Net product sales of meter-based Triage products in the U.S. totaled \$40.9 million during the six months ended June 30, 2013, as compared to \$91.1 million during the six months ended June 30, 2012. Excluding the impact of acquisitions, the increase in flu-related sales during the comparable periods and the impact of the reduction in net product sales from meter-based Triage products in the U.S., the currency-adjusted organic growth for our professional diagnostics net product sales and services revenue was approximately \$48.5 million, or 5%, from the six months ended June 30, 2012 to the six months ended June 30, 2013.

Within our professional diagnostics business segment, net product sales and services revenue for our cardiology business decreased by approximately \$31.1 million, or 12%, to \$233.4 million for the six months ended June 30, 2013, from \$264.4 million for the six months ended June 30, 2012, driven principally by the impact of the FDA review of certain of our meter-based Triage products in the U.S. Net product sales and services revenue for our infectious disease business increased by approximately \$58.7 million, or 20%, to \$347.6 million for the six months ended June 30, 2013, from \$288.8 million for the six months ended June 30, 2012. The change was driven principally by an increase in malaria-related sales during the comparable periods. Net product sales and services revenue for our toxicology business increased by approximately \$33.3 million, or 12%, to \$314.9 million for the six months ended June 30, 2013, from \$281.7 million for the six months ended June 30, 2012, with our recent acquisitions of eScreen, Amedica, and Branan, contributing a combined net \$48.0 million of the non-currency adjusted increase. Partially offsetting the increase in net product sales and services revenue for our toxicology business contributed by acquisitions was a \$15.3 million decrease in net product sales related to our Triage toxicology products and a reduction in commercial pricing for our pain and rehab businesses which was implemented in the second quarter of 2012. Our diabetes business increased by approximately \$60.0 million, or 92%, to \$125.0 million for the six months ended June 30, 2013, from \$65.0 million for the six months ended June 30, 2012. Our diabetes business increased by approximately \$60.0 million, or 92%, to \$125.0 million for the six months ended June 30, 2013, from \$65.0 million for the six months ended June 30, 2012. The increase was primarily the result of our recent acquisitions of AmMed, NationsHealth, Discount Diabetics and the Liberty business, which contributed a combined net \$52.3 million of the non-currency adjusted increase.

**Table of Contents***Health Information Solutions*

The following table summarizes our net product sales and services revenue from our health information solutions business segment by groups of similar products and services for the three and six months ended June 30, 2013 and 2012 (in thousands):

	Three Months Ended June 30,		%	Six Months Ended June 30,		%
	2013	2012	Change	2013	2012	Change
Disease and case management	\$ 52,578	\$ 54,512	(4)%	\$ 106,704	\$ 107,894	(1)%
Wellness	27,230	29,567	(8)%	53,530	56,591	(5)%
Women s & children s health	29,256	31,313	(7)%	58,336	61,084	(4)%
Patient self-testing services	25,711	23,198	11%	50,412	43,805	15%
<b>Health information solutions net product sales and services revenue</b>	<b>\$ 134,775</b>	<b>\$ 138,590</b>	<b>(3)%</b>	<b>\$ 268,982</b>	<b>\$ 269,374</b>	<b>%</b>

Our health information solutions net product sales and services revenue decreased by \$3.8 million, or 3%, to \$134.8 million for the three months ended June 30, 2013, from \$138.6 million for the three months ended June 30, 2012. Net product sales and services revenues from our disease and case management, wellness and women s and children s health businesses each decreased during the three months ended June 30, 2013, compared to the three months ended June 30, 2012, as we experienced customer terminations, lower state enrollments in wellness programs and lower revenue from homecare services in these businesses, respectively. Our patient self-testing services net product sales and services revenue increased approximately \$2.5 million, or 11%, to \$25.7 million for the three months ended June 30, 2013, from \$23.2 million for the three months ended June 30, 2012, principally driven by an increase in our home coagulation monitoring programs resulting from a larger patient population and a simultaneous reduction in customer attrition rates.

Our health information solutions net product sales and services revenue was \$269.0 million for the six months ended June 30, 2013, and was relatively flat compared to \$269.4 million for the six months ended June 30, 2012. Net product sales and service revenue from our disease and case management, wellness and women s and children s health businesses each decreased during the six months ended June 30, 2013, compared to the six months ended June 30, 2012, as we experienced customer terminations, lower state enrollments in wellness programs and lower revenue from homecare services in these businesses, respectively. Our patient self-testing services net product sales and services revenue increased approximately \$6.6 million, or 15%, to \$50.4 million for the six months ended June 30, 2013, from \$43.8 million for the six months ended June 30, 2012, principally driven by an increase in our home coagulation monitoring programs resulting from a larger patient population and a simultaneous reduction in customer attrition rates.

*Consumer Diagnostics*

Net product sales and services revenue from our consumer diagnostics business segment revenue increased by \$2.9 million, or 13%, to \$24.7 million for the three months ended June 30, 2013, from \$21.8 million for the three months ended June 30, 2012. Net product sales by our 50/50 joint venture with P&G, or SPD, were \$47.7 million during the three months ended June 30, 2013, as compared to \$51.3 million during the three months ended June 30, 2012.

Net product sales and services revenue from our consumer diagnostics business segment revenue increased by \$3.3 million, or 8%, to \$47.1 million for the six months ended June 30, 2013, from \$43.8 million for the six months ended June 30, 2012. Net product sales by our 50/50 joint venture with P&G, or SPD, were \$90.8 million during the six months ended June 30, 2013, as compared to \$97.4 million during the six months ended June 30, 2012.

**License and Royalty Revenue.** License and royalty revenue represents license and royalty fees from intellectual property license agreements with third parties. License and royalty revenue increased by approximately \$1.6 million, or 50%, to \$4.9 million for the three months ended June 30, 2013, from \$3.2 million for the three months ended June 30, 2012. The increase in royalty revenue for the three months ended June 30, 2013, compared to the three months ended June 30, 2012, is primarily a result of new licensing agreements and higher royalties earned under existing licensing agreements.

License and royalty revenue increased by approximately \$2.8 million, or 45%, to \$8.9 million for the six months ended June 30, 2013, from \$6.1 million for the six months ended June 30, 2012. The increase in royalty revenue for the six months ended June 30, 2013, compared to the six months ended June 30, 2012, is primarily a result of new licensing agreements and higher royalties earned under existing licensing agreements.



## Edgar Filing: ALERE INC. - Form 10-Q

**Gross Profit and Margin.** Gross profit increased by \$28.9 million, or 8%, to \$384.5 million for the three months ended June 30, 2013, from \$355.6 million for the three months ended June 30, 2012. The increase in gross profit during the three months ended June 30, 2013, compared to the three months ended June 30, 2012, was largely attributed to the increase in net product sales and services revenue resulting from acquisitions.

**Table of Contents**

Gross profit increased by \$40.1 million, or 6%, to \$748.7 million for the six months ended June 30, 2013, from \$708.7 million for the six months ended June 30, 2012. The increase in gross profit during the six months ended June 30, 2013, compared to the six months ended June 30, 2012, was largely attributed to the increase in net product sales and services revenue resulting from acquisitions.

Cost of net revenue included amortization expense of \$17.1 million and \$17.5 million for the three months ended June 30, 2013 and 2012, respectively. Included in the cost of net revenue for the three months ended June 30, 2013 was a \$0.7 million non-cash charge relating to the write-up of inventory to fair value in connection with our acquisition of Epocal.

Cost of net revenue included amortization expense of \$36.3 million and \$33.2 million for the six months ended June 30, 2013 and 2012, respectively, and \$1.2 million and \$4.7 million of non-cash charges relating to the write-up of inventory to fair value in connection with certain acquisitions during the six months ended June 30, 2013 and 2012, respectively.

Overall gross margin for each of the three and six months ended June 30, 2013 was 50%, compared to 51% and 52% for the three and six months ended June 30, 2012, respectively.

**Gross Profit from Net Product Sales and Services Revenue, Total and by Business Segment.** Gross profit from net product sales and services revenue increased by \$26.9 million, or 8%, to \$381.1 million for the three months ended June 30, 2013, from \$354.2 million for the three months ended June 30, 2012. Gross profit from net product sales and services revenue increased by \$37.0 million, or 5%, to \$743.1 million for the six months ended June 30, 2013, from \$706.0 million for the six months ended June 30, 2012. Gross profit from net product sales and services revenue by business segment for the three and six months ended June 30, 2013 and 2012 is as follows (in thousands):

	Three Months Ended June 30,		%	Six Months Ended June 30,		%
	2013	2012	Change	2013	2012	Change
Professional diagnostics	\$ 314,864	\$ 285,861	10%	\$ 615,039	\$ 576,770	7%
Health information solutions	60,781	62,733	(3)%	118,131	120,102	(2)%
Consumer diagnostics	5,476	5,629	(3)%	9,900	9,158	8%
Gross profit from net product sales and services revenue	\$ 381,121	\$ 354,223	8%	\$ 743,070	\$ 706,030	5%

*Professional Diagnostics*

Gross profit from our professional diagnostics net product sales and services revenue increased by \$29.0 million, or 10%, to \$314.9 million for the three months ended June 30, 2013, compared to \$285.9 million for the three months ended June 30, 2012, principally as a result of gross profit earned on revenue from acquired businesses, as discussed above. Gross profit was negatively impacted by a decrease in our U.S. meter-based Triage product sales, as discussed above. The FDA matters relating to our meter-based Triage products also resulted in incremental costs during the three months ended June 30, 2013, principally due to unfavorable manufacturing variances and the lost margin on the reduced volume of tests sold during the three months ended June 30, 2013, as compared to the three months ended June 30, 2012. Cost of professional diagnostics net product sales and services revenue during each of the three months ended June 30, 2013 and 2012, included a non-cash charge of \$0.7 million relating to the write-up of inventory to fair value in connection with a recent acquisition. Reducing gross profit during the three months ended June 30, 2013 was \$0.2 million in restructuring charges.

Gross profit from our professional diagnostics net product sales and services revenue increased by \$38.3 million, or 7%, to \$615.0 million for the six months ended June 30, 2013, compared to \$576.8 million for the six months ended June 30, 2012, principally as a result of gross profit earned on revenue from acquired businesses, as discussed above. Gross profit was negatively impacted by a decrease in our U.S. meter-based Triage product sales and a reduction in commercial pricing for our pain and rehab businesses, as discussed above. The FDA matters relating to our meter-based Triage products also resulted in incremental costs during the six months ended June 30, 2013, principally due to unfavorable manufacturing variances and the lost margin on the reduced volume of tests sold during the six months ended June 30, 2013, as compared to the three months ended June 30, 2012. Cost of professional diagnostics net product sales and services revenue during the six months ended June 30, 2013 and 2012, included a non-cash charge of \$1.2 million and \$4.7 million, respectively, relating to the write-up of inventory to fair value in connection with certain acquisitions. Reducing gross profit during the six months ended June 30, 2013 and 2012 was \$0.4 million and \$0.6 million, respectively, in restructuring charges.

## Edgar Filing: ALERE INC. - Form 10-Q

Cost of professional diagnostics net product sales and services revenue included amortization expense of \$15.7 million and \$15.5 million during the three months ended June 30, 2013 and 2012, respectively. Cost of professional diagnostics net product sales and services revenue included amortization expense of \$33.1 million and \$29.4 million during the six months ended June 30, 2013 and 2012, respectively.

---

**Table of Contents**

As a percentage of our professional diagnostics net product sales and services revenue, gross margin for the three and six months ended June 30, 2013 was 53% and 52%, respectively, compared to 53% and 55% for the three and six months ended June 30, 2012, respectively. Increased revenue from our recently acquired toxicology businesses, which contribute lower-than-segment-average gross margin, and a decrease in our U.S. meter-based Triage product sales, which contribute higher-than-segment-average gross margin, contributed to the decrease in gross margin in the six months ended June 30, 2013 from the six months ended June 30, 2012.

*Health Information Solutions*

Gross profit from our health information solutions net product sales and services revenue decreased by \$2.0 million, or 3%, to \$60.8 million for the three months ended June 30, 2013, compared to \$62.7 million for the three months ended June 30, 2012. Reducing gross profit during the three months ended June 30, 2013 and 2012 was \$0.6 million and \$0.1 million in restructuring charges, respectively. Gross profit from our health information solutions net product sales and services revenue decreased by \$2.0 million, or 2%, to \$118.1 million for the six months ended June 30, 2013, compared to \$120.1 million for the six months ended June 30, 2012. Reducing gross profit during the six months ended June 30, 2013 and 2012 was \$1.0 million and \$0.5 million in restructuring charges, respectively.

Cost of health information solutions net product sales and services revenue included amortization expense of \$1.2 million and \$1.6 million during the three months ended June 30, 2013 and 2012, respectively. Cost of health information solutions net product sales and services revenue included amortization expense of \$2.7 million and \$3.2 million during the six months ended June 30, 2013 and 2012, respectively.

As a percentage of our health information solutions net product sales and services revenue, gross margin for the three and six months ended June 30, 2013 was 45% and 44%, respectively, compared to 45% for both the three and six months ended June 30, 2012.

*Consumer Diagnostics*

Gross profit from our consumer diagnostics net product sales and services revenue decreased by \$0.2 million, or 3%, to \$5.5 million for the three months ended June 30, 2013, from \$5.6 million for the three months ended June 30, 2012. Gross profit from our consumer diagnostics net product sales and services revenue increased by \$0.7 million, or 8%, to \$9.9 million for the six months ended June 30, 2013, compared to \$9.2 million for the six months ended June 30, 2012. The increase in gross profit was primarily the result of a one-time cost of goods sold adjustment totaling approximately \$0.7 million related to our manufacturing agreement with SPD recorded during the six months ended June 30, 2012.

Cost of consumer diagnostics net product sales and services revenue included amortization expense of \$0.2 million and \$0.3 million during the three months ended June 30, 2013 and 2012, respectively. Cost of consumer diagnostics net product sales and services revenue included amortization expense of \$0.5 million and \$0.6 million during the six months ended June 30, 2013 and 2012, respectively.

As a percentage of our consumer diagnostics net product sales and services revenue, gross margin for the three and six months ended June 30, 2013 was 22% and 21%, respectively, compared to 26% and 21% for the three and six months ended June 30, 2012, respectively.

**Research and Development Expense.** Research and development expense was \$40.5 million for the three months ended June 30, 2013, compared to \$40.4 million for the three months ended June 30, 2012. Research and development expense during the three months ended June 30, 2013 is reported net of grant funding of \$1.8 million arising from the research and development funding relationship with the Bill and Melinda Gates Foundation that we entered into in February 2013. Included in research and development expense for the three months ended June 30, 2013 were restructuring charges associated with our various restructuring plans to integrate our newly-acquired businesses totaling approximately \$0.6 million. Restructuring charges included in research and development expense during the three months ended June 30, 2012 totaled approximately \$14,000. Amortization expense of \$1.2 million and \$1.5 million was included in research and development expense for the three months ended June 30, 2013 and 2012, respectively.

Research and development expense increased by \$2.5 million, or 3%, to \$82.0 million for the six months ended June 30, 2013, from \$79.4 million for the six months ended June 30, 2012. Research and development expense during the six months ended June 30, 2013 is reported net of grant funding of approximately \$2.4 million arising from the research and development funding relationship with the Bill and Melinda Gates Foundation that we entered into in February 2013. Included in research and development expense for each of the six months ended June 30, 2013 and 2012 were restructuring charges totaling approximately \$0.6 million associated with our various restructuring plans to integrate our newly-acquired businesses. Amortization expense of \$2.5 million and \$3.9 million was included in research and development expense for the three months ended June 30, 2013 and 2012, respectively.



---

**Table of Contents**

Research and development expense as a percentage of net revenue was 5% for both the three and six months ended June 30, 2013, compared to 6% for both the three and six months ended June 30, 2012.

**Sales and Marketing Expense.** Sales and marketing expense was \$159.4 million for the three months ended June 30, 2013, compared to \$159.3 million for the three months ended June 30, 2012. Amortization expense of \$57.3 million and \$60.4 million was included in sales and marketing expense for the three months ended June 30, 2013 and 2012, respectively. Restructuring charges associated with our various restructuring plans to integrate our newly-acquired businesses totaling approximately \$0.2 million were included in sales and marketing expense for each of the three months ended June 30, 2013 and 2012.

Sales and marketing expense decreased by \$2.0 million, or 1%, to \$315.9 million for the six months ended June 30, 2013, from \$317.9 million for the six months ended June 30, 2012. The decrease in sales and marketing expense was primarily driven by lower amortization expense during the six months ended June 30, 2013, compared to the six months ended June 30, 2012. Amortization expense of \$110.9 million and \$118.1 million was included in sales and marketing expense for the six months ended June 30, 2013 and 2012, respectively. Restructuring charges associated with our various restructuring plans to integrate our newly-acquired businesses totaling approximately \$1.3 million and \$1.0 million were included in sales and marketing expense for the six months ended June 30, 2013 and 2012, respectively.

Sales and marketing expense as a percentage of net revenue was 21% for each of the three and six months ended June 30, 2013, compared to 23% for each of the three and six months ended June 30, 2012, respectively.

**General and Administrative Expense.** General and administrative expense increased by approximately \$18.7 million, or 15%, to \$140.2 million for the three months ended June 30, 2013, from \$121.5 million for the three months ended June 30, 2012. The increase in general and administrative expense relates primarily to additional spending related to newly-acquired businesses. During the three months ended June 30, 2013 and 2012, we recorded expense of \$5.3 million and income of \$6.7 million, respectively, in connection with fair value adjustments to acquisition-related contingent consideration obligations. Acquisition-related costs of \$0.4 million and \$3.8 million were included in general and administrative expense for the three months ended June 30, 2013 and 2012, respectively. Restructuring charges associated with our various restructuring plans to integrate our newly-acquired businesses totaling approximately \$6.5 million and \$1.1 million were included in general and administrative expense for the three months ended June 30, 2013 and 2012, respectively. Amortization expense of \$3.5 million and \$2.0 million was included in general and administrative expense for the three months ended June 30, 2013 and 2012, respectively.

General and administrative expense increased by approximately \$34.1 million, or 14%, to \$276.0 million for the six months ended June 30, 2013, from \$241.9 million for the six months ended June 30, 2012. The increase in general and administrative expense relates primarily to additional spending related to newly-acquired businesses. During the six months ended June 30, 2013 and 2012, we recorded expense of \$16.3 million and income of \$1.6 million, respectively, in connection with fair value adjustments to acquisition-related contingent consideration obligations. Acquisition-related costs of \$1.3 million and \$5.3 million were included in general and administrative expense for the six months ended June 30, 2013 and 2012, respectively. Restructuring charges associated with our various restructuring plans to integrate our newly-acquired businesses totaling approximately \$8.7 million and \$4.2 million were included in general and administrative expense for the six months ended June 30, 2013 and 2012, respectively. Amortization expense of \$5.4 million and \$4.1 million was included in general and administrative expense for the six months ended June 30, 2013 and 2012, respectively.

General and administrative expense as a percentage of net revenue was 18% for each of the three and six months ended June 30, 2013, compared to 17% and 18% for the three and six months ended June 30, 2012, respectively.

**Interest Expense.** Interest expense includes interest charges and the amortization of deferred financing costs and original issue discounts associated with certain debt issuances. Interest expense increased by \$36.9 million, or 66%, to \$92.5 million for the three months ended June 30, 2013, from \$55.5 million for the three months ended June 30, 2012. The increase is principally due to a \$35.6 million loss recorded in connection with the repurchase of our 9% senior subordinated notes during the three months ended June 30, 2013, along with higher interest expense recorded in connection with higher overall outstanding debt balances during the second quarter of 2013, compared to the overall outstanding debt balances during the second quarter of 2012.

Interest expense increased by \$43.6 million, or 41%, to \$149.9 million for the six months ended June 30, 2013, from \$106.3 million for the six months ended June 30, 2012. The increase is principally due to a \$35.6 million loss recorded in connection with the repurchase of our 9% senior subordinated notes during the six months ended June 30, 2013, along with higher interest expense recorded in connection with higher overall outstanding debt balances during the first half of 2013, compared to the overall outstanding debt balances during the first half of 2012.



**Table of Contents**

**Other Income (Expense), Net.** Other income (expense), net includes interest income, realized and unrealized foreign exchange gains and losses, and other income and expense. The components and the respective amounts of other income (expense), net are summarized as follows (in thousands):

	Three Months Ended June 30,			Six Months Ended June 30,		
	2013	2012	Change	2013	2012	Change
Interest income	\$ 780	\$ 503	\$ 277	\$ 1,803	\$ 1,065	\$ 738
Foreign exchange gains (losses), net	926	(5,423)	6,349	459	(6,197)	6,656
Other	(643)	8,731	(9,374)	(1,669)	20,774	(22,443)
Total other income (expense), net	\$ 1,063	\$ 3,811	\$ (2,748)	\$ 593	\$ 15,642	\$ (15,049)

Other income of \$8.7 million for the three months ended June 30, 2012 includes a \$7.2 million gain recorded on the sale of property and \$1.4 million of income associated with legal settlements related to intellectual property litigation. Other income of \$20.8 million for the six months ended June 30, 2012 includes a \$13.5 million final royalty termination payment received from Quidel, a \$7.2 million gain recorded on the sale of property and \$1.4 million of income associated with legal settlements related to intellectual property litigation.

**Provision (Benefit) for Income Taxes.** The provision (benefit) for income taxes increased to a \$17.9 million provision for the three months ended June 30, 2013, from a \$0.5 million benefit for the three months ended June 30, 2012. Our effective tax rate is calculated based on projected income across many different jurisdictions and can change based on the location of income, losses and credits. The change in the effective tax rate, from the three months ended June 30, 2012 to the three months ended June 30, 2013, results primarily from changes in income, as well as the jurisdictional mix of that income, during the three months ended June 30, 2013, an increase to certain tax reserves under the principles of accounting for uncertain tax positions in accordance with ASC 740, *Income Taxes*, and increases in certain current and prior year tax losses not benefited.

The benefit for income taxes increased by \$17.1 million to \$19.0 million for the six months ended June 30, 2013, from a \$1.9 million benefit for the six months ended June 30, 2012. The income tax benefits for the six months ended June 30, 2013 and 2012 relate to federal, foreign and state income tax provisions and benefits. The increase in the effective income tax rate and benefit for income taxes during the six months ended June 30, 2013, compared to the six months ended June 30, 2012, is primarily a result of changes in income and the jurisdictional mix of that income, the extension of the federal research and development tax credit for 2012, an increase to certain tax reserves under the principles of accounting for uncertain tax positions in accordance with ASC 740, *Income Taxes*, and increases in certain current and prior year tax losses not benefited.

**Equity Earnings in Unconsolidated Entities, Net of Tax.** Equity earnings in unconsolidated entities is reported net of tax and includes our share of earnings in entities that we account for under the equity method of accounting. Equity earnings (losses) in unconsolidated entities, net of tax for the three and six months ended June 30, 2013 reflects the following: (i) our 50% interest in SPD in the amount of \$4.2 million and \$6.7 million, respectively, (ii) our 40% interest in Vedalab S.A., or Vedalab, in the amount of \$(0.1) million and \$0.1 million, respectively, and (iii) our 49% interest in TechLab, Inc., or TechLab, in the amount of \$0.5 million and \$0.8 million, respectively. Equity earnings in unconsolidated entities, net of tax for the three and six months ended June 30, 2012 reflects the following: (i) our 50% interest in SPD in the amount of \$3.3 million and \$6.1 million, respectively, (ii) our 40% interest Vedalab in the amount of \$0.1 million and \$0.1 million, respectively, and (iii) our 49% interest in TechLab in the amount of \$0.5 million and \$1.2 million, respectively.

**Net Loss Available to Common Stockholders.** For the three months ended June 30, 2013, we generated a net loss available to common stockholders of \$65.9 million, or \$0.81 per diluted common share. For the three months ended June 30, 2012, we generated a net loss available to common stockholders of \$18.2 million, or \$0.23 per diluted common share. Net loss available to common stockholders reflects \$5.3 million of preferred stock dividends paid during each of the three months ended June 30, 2013 and 2012. For the six months ended June 30, 2013, we generated a net loss available to common stockholders of \$58.7 million, or \$0.72 per diluted common share. For the six months ended June 30, 2012, we generated a net loss available to common stockholders of \$22.3 million, or \$0.28 per diluted common share. Net loss available to common stockholders reflects \$10.6 million of preferred stock dividends paid during each of the six months ended June 30, 2013 and 2012. See Note 5 of the accompanying consolidated financial statements for the calculation of net loss per common share.



**Table of Contents****Liquidity and Capital Resources**

Based upon our current working capital position, current operating plans and expected business conditions, we expect to fund our short- and long-term working capital needs primarily using existing cash and our operating cash flow, and we expect our working capital position to improve as we improve our future operating margins, grow our business through new product and service offerings and divest of non-core businesses and assets. As of June 30, 2013, we had \$320.5 million of cash and cash equivalents, of which \$245.2 million was held by domestic subsidiaries and \$75.3 million was held by foreign entities. As of June 30, 2012, we had \$303.7 million of cash and cash equivalents, of which \$93.8 million was held by domestic subsidiaries and \$209.9 million was held by foreign entities. We do not plan to repatriate cash held by foreign entities due to adverse tax implications, including incremental U.S. tax liabilities and potential foreign withholding tax liabilities.

We may also utilize our secured credit facility or other new sources of financing to fund a portion of our capital needs and other commitments, including our contractual contingent consideration obligations and future acquisitions. As of June 30, 2013, we had outstanding borrowings totaling \$197.5 million under the \$250.0 million revolving line of credit under our secured credit facility, with \$52.5 million available to us for additional borrowings. Our ability to access the capital markets may be impacted by the amount of our outstanding debt and equity and the extent to which our assets are encumbered by our outstanding secured debt. The terms and conditions of our outstanding debt instruments also contain covenants which expressly restrict our ability to incur additional indebtedness and conduct other financings. As of June 30, 2013, we had \$3.9 billion in outstanding indebtedness comprised of \$2.4 billion under our secured credit facility, including borrowings under our revolving line of credit, \$450.0 million of 7.25% senior notes due 2018, \$400.0 million of 8.625% senior subordinated notes due 2018, \$425.0 million of 6.5% senior subordinated notes due 2020, and \$150.0 million of 3% convertible senior subordinated notes due 2016.

If the capital and credit markets experience volatility or the availability of funds is limited, we may incur increased costs associated with issuing debt instruments. In addition, it is possible that our ability to access the capital and credit markets could be limited by these or other factors at a time when we would like, or need, to do so, which could have an adverse impact on our ability to refinance maturing debt and/or react to changing economic and business conditions.

Our funding plans for our working capital needs and other commitments may be adversely impacted by unexpected costs associated with integrating the operations of newly-acquired companies, executing our cost-savings strategies and prosecuting and defending our existing lawsuits and/or unforeseen lawsuits against us. We also cannot be certain that our underlying assumed levels of revenues and expenses will be realized. In addition, we intend to continue to make investments in our research and development efforts related to the substantial intellectual property portfolio we own. We may also choose to further expand our research and development efforts and may pursue the acquisition of new products and technologies through licensing arrangements, business acquisitions, or otherwise. We may also choose to make significant investment to pursue legal remedies against potential infringers of our intellectual property rights. If we decide to engage in such activities, or if our operating results fail to meet our expectations, we could be required to seek additional funding through public or private financings or other arrangements. In such event, adequate funds may not be available when needed or may be available only on terms which could have a negative impact on our business and results of operations. In addition, if we raise additional funds by issuing equity or convertible securities, dilution to then-existing stockholders may result.

<b>Cash Flow Summary (in thousands)</b>	<b>Six Months Ended June 30,</b>	
	<b>2013</b>	<b>2012</b>
Net cash provided by operating activities	\$ 98,759	\$ 166,230
Net cash used in investing activities	(205,196)	(353,068)
Net cash provided by financing activities	103,386	189,449
Foreign exchange effect on cash and cash equivalents	(4,748)	1,955
Net increase (decrease) in cash and cash equivalents	(7,799)	4,566
Cash and cash equivalents, beginning of period	328,346	299,173
Cash and cash equivalents, end of period	\$ 320,547	\$ 303,739

*Summary of Changes in Cash Position*

Cash and cash equivalents decreased \$7.8 million during the six months ended June 30, 2013, compared to an increase of \$4.6 million during the six months ended June 30, 2012. Our primary sources of cash during the six months ended June 30, 2013 included \$98.8 million generated by our operating activities, \$435.5 million of net proceeds received in connection with long-term debt issuances, which included \$425.0 million of

## Edgar Filing: ALERE INC. - Form 10-Q

gross proceeds received in connection with the issuance of our 6.5% senior subordinated notes, \$166.5 million of net proceeds under various revolving credit facilities, which included \$190.0 million borrowed against our secured credit facility revolving line-of-credit, \$10.6 million return of capital related to an equity investment, \$7.8 million of cash received from common stock issuances under employee stock option and stock purchase plans, \$4.6 million in proceeds from the sale

**Table of Contents**

of property and equipment and a \$17.0 million decrease related to other assets. Our primary uses of cash during the six months ended June 30, 2013 were \$437.8 million of cash payments on long-term debt, which included \$400.0 million of cash payments related to the repurchase of our 9% senior subordinated notes, \$166.0 million net cash paid for acquisitions, \$64.6 million of capital expenditures, \$26.6 million related to payments of acquisition-related contingent consideration obligations, \$19.0 million related to tender offer consideration and call premium incurred in connection with the repurchase of our 9% senior subordinated notes, \$10.6 million for cash dividends paid on our Series B Preferred Stock, \$9.0 million related to the payment of debt-related financing costs and \$3.5 million for payment of capital lease obligations. Fluctuations in foreign currencies negatively impacted our cash balance by \$4.7 million during the six months ended June 30, 2013.

Our primary sources of cash during the six months ended June 30, 2012 included \$166.2 million generated by our operating activities, approximately \$198.0 million of proceeds received in connection with the Incremental B-2 term loans entered into as part of our secured credit facility, \$47.5 million borrowed against our secured credit facility revolving line of credit, \$21.7 million of proceeds received from the sale of property, plant and equipment, \$8.7 million from common stock issuances under employee stock option and stock purchase plans and a \$6.1 million return of capital from SPD. Our primary uses of cash during the six months ended June 30, 2012 included \$310.2 million net cash paid for acquisitions, \$69.5 million of capital expenditures, \$29.9 million related to the repayment of long-term debt obligations, \$7.7 million related to an increase in other assets, \$10.6 million for cash dividends paid on our Series B Preferred stock, \$6.5 million paid for contingent purchase price consideration, \$6.2 million related to the repayment of short-term debt obligations and \$3.3 million for payment of capital lease obligations. Fluctuations in foreign currencies positively impacted our cash balance by \$2.0 million during the six months ended June 30, 2012.

*Cash Flows from Operating Activities*

Net cash provided by operating activities during the six months ended June 30, 2013 was \$98.8 million, which resulted from a net loss of \$47.9 million and \$74.9 million of cash utilized by changes in net working capital requirements during the period, offset by \$221.5 million of non-cash items. The \$221.5 million of non-cash items included, among other items, \$213.9 million related to depreciation and amortization, \$10.2 million of interest expense related to the amortization of deferred financing costs and original issue discounts, \$8.8 million related to non-cash stock-based compensation, \$34.9 million related to other non-cash items and a \$1.2 million non-cash charge related to the write up of inventory to fair value in connection with the acquisition of Epocal, Inc., or Epocal, partially offset by a \$44.1 million decrease related to changes in our deferred tax assets and liabilities, which resulted in part from amortization of intangible assets, and \$7.5 million in equity earnings in unconsolidated entities, net of tax.

Net cash provided by operating activities during the six months ended June 30, 2012 was \$166.2 million, which resulted from a net loss of \$11.9 million, \$193.9 million of non-cash items and \$15.9 million of cash utilized by changes in net working capital requirements during the period. The \$193.9 million of non-cash items included, among other items, \$211.6 million related to depreciation and amortization, a \$4.7 million non-cash charge relating to the write-up of inventory to fair value in connection with the acquisition of Axis-Shield, \$10.7 million of interest expense related to the amortization of deferred financing costs and original issue discounts and \$8.2 million related to stock-based compensation, partially offset by a \$27.4 million decrease related to changes in our deferred tax assets and liabilities, which partially resulted from amortization of intangible assets, a \$7.4 million decrease attributable to equity earnings in unconsolidated entities and a \$5.9 million gain on the sale of property, plant and equipment.

*Cash Flows from Investing Activities*

Our investing activities during the six months ended June 30, 2013 utilized \$205.2 million of cash, including \$166.0 million net cash paid for acquisitions, \$64.6 million of capital expenditures and an increase in our restricted cash balance of \$6.8 million which was principally driven by \$7.9 million of cash received from the Bill and Melinda Gates Foundation, partially offset by a \$10.6 million return of capital related to an equity investment, \$4.6 million of proceeds received from the sale of property and equipment and a \$17.0 million decrease related to other assets.

Our investing activities during the six months ended June 30, 2012 utilized \$353.1 million of cash, including \$310.2 million net cash paid for acquisitions, \$69.5 million of capital expenditures and \$7.7 million related to an increase in other assets, offset by \$21.7 million of proceeds received from the sale of property, plant and equipment and a \$6.1 million return of capital from SPD.

*Cash Flows from Financing Activities*

Net cash provided by financing activities during the six months ended June 30, 2013 was \$103.4 million. Financing activities providing cash during the six months ended June 30, 2013 primarily included \$435.5 million of net proceeds received in connection with long-term debt issuances, which included \$425.0 million of gross proceeds received in connection with the issuance of our 6.5% senior subordinated notes, \$166.5 million of net proceeds under various revolving credit facilities, which included \$190.0 million borrowed against our secured credit

## Edgar Filing: ALERE INC. - Form 10-Q

facility revolving line-of-credit, and \$7.8 million of cash received from common stock issuances under employee stock option and stock purchase plans. We utilized \$437.8 million of cash payments on long-term debt, which included \$400.0 million of cash payments related to the repurchase of our 9% senior subordinated notes, \$26.6 million for payments of acquisition-related contingent consideration obligations, \$19.0 million related to tender offer consideration and call premium incurred in connection with the repurchase of our 9% senior subordinated notes, \$10.6 million for dividend payments related to our Series B preferred stock, \$9.0 million related to the payment of debt-related financing costs and \$3.5 million for payment of capital lease obligations.

**Table of Contents**

Net cash provided by financing activities during the six months ended June 30, 2012 was \$189.4 million. Financing activities providing cash during the six months ended June 30, 2012 primarily included approximately \$198.0 million of net proceeds received in connection with the Incremental B-2 term loans entered into as part of our secured credit facility, \$47.5 million borrowed against our secured credit facility revolving line of credit and \$8.7 million of cash received from common stock issuances under employee stock option and stock purchase plans. We utilized approximately \$29.9 million in connection with the repayment of long-term debt obligations, \$6.2 million for the repayment of short-term debt obligations, \$10.6 million for cash dividends paid on our Series B Preferred stock, \$6.5 million paid for contingent purchase price consideration and \$3.3 million for payment of capital lease obligations.

As of June 30, 2013, we had an aggregate of \$17.6 million in outstanding capital lease obligations which are payable through 2018.

*Income Taxes*

As of December 31, 2012, we had approximately \$60.6 million of domestic NOL and domestic capital loss carryforwards, approximately \$981.1 million of state NOL carryforwards and \$211.6 million of foreign NOL and foreign capital loss carryforwards, which either expire on various dates through 2032 or can be carried forward indefinitely. As of December 31, 2012, we had approximately \$57.7 million of domestic research and development, foreign tax and alternative minimum tax credits which either expire on various dates through 2031 or can be carried forward indefinitely. These loss carryforwards and tax credits may be available to reduce future federal, state and foreign taxable income, if any, and are subject to review and possible adjustment by the appropriate tax authorities.

Furthermore, all domestic losses and credits are subject to the limitations imposed by Sections 382 and 383 of the Internal Revenue Code, and may be limited in the event of certain cumulative changes in ownership interests of significant shareholders over a three-year period in excess of 50%. Sections 382 and 383 impose an annual limitation on the use of these losses or credits to an amount equal to the value of the company at the time of the ownership change multiplied by the long-term tax exempt rate. We have recorded a valuation allowance against a portion of the deferred tax assets related to our NOLs and credits and certain of our other deferred tax assets to reflect uncertainties that might affect the realization of such deferred tax assets, as these assets can only be realized via profitable operations.

**Off-Balance Sheet Arrangements**

We had no material off-balance sheet arrangements as of June 30, 2013.

**Contractual Obligations**

The following summarizes our principal contractual obligations as of June 30, 2013 that have changed significantly since December 31, 2012 and the effects such obligations are expected to have on our liquidity and cash flow in future periods. Contractual obligations that were presented in our Annual Report on Form 10-K, as amended, for the year ended December 31, 2012, but omitted below, represent those that have not changed significantly since that date.

	Total	Payments Due by Period (in thousands)			Thereafter
		2013	2014-2015	2016-2017	
Long-term debt obligations	\$ 3,860,451	\$ 34,812	\$ 97,407	\$ 2,450,855	\$ 1,277,377

With respect to our February 1, 2013 acquisition of Epocal, the terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. The maximum amount of the earn-out payments is \$90.5 million, of which \$15.0 million was paid at the acquisition closing date. The maximum amount of the management incentive payments is \$9.4 million.

**Critical Accounting Policies**

The discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements in accordance with generally accepted accounting principles requires us to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On a quarterly basis, we evaluate our estimates, including those related to revenue recognition and related allowances, bad debt, inventory, valuation of long-lived assets, including intangible assets and goodwill, income taxes, including any



**Table of Contents**

valuation allowance for our net deferred tax assets, contingencies and litigation, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.

There have been no significant changes in our critical accounting policies or management estimates since December 31, 2012. A comprehensive discussion of our critical accounting policies and management estimates is included in Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K, as amended for the year ended December 31, 2012.

**Recent Accounting Pronouncements**

See Note 17 in the notes to the consolidated financial statements included in this Quarterly Report on Form 10-Q, regarding the impact of certain recent accounting pronouncements on our consolidated financial statements.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Our market risks, and the ways we manage them, are summarized in Part II, Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" of our Annual Report on Form 10-K, as amended, for the year ended December 31, 2012. There have been no material changes to our market risks or management of such risks since that date.

**ITEM 4. CONTROLS AND PROCEDURES***Evaluation of Disclosure Controls and Procedures*

Our management evaluated, with the participation of our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our management, including the CEO and CFO, concluded that our disclosure controls and procedures were effective at that time. We and our management understand nonetheless that controls and procedures, no matter how well designed and operated, can provide only reasonable assurances of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating and implementing possible controls and procedures. In reaching their conclusions stated above regarding the effectiveness of our disclosure controls and procedures, our CEO and CFO concluded that such disclosure controls and procedures were effective as of such date at the reasonable assurance level.

*Changes in Internal Control over Financial Reporting*

There was no change in our internal control over financial reporting that occurred during the most recent fiscal quarter covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**PART II OTHER INFORMATION****ITEM 6. EXHIBITS****Exhibits:**

Exhibit No.	Description
4.1	Fourteenth Supplemental Indenture to Indenture dated as of May 12, 2009 (to add the guarantees of Alere Informatics, Inc., Alere Wellogic, LLC, ATS Laboratories, Inc., Avee Laboratories Inc., eScreen, Inc., Global Analytical Development LLC, Ionian

## Edgar Filing: ALERE INC. - Form 10-Q

Technologies Inc., Pembroke Occupational Health, Inc., Screen Tox, Inc., and Standing Stone, Inc.) dated as of April 3, 2013 among Alere Informatics, Inc., Alere Wellogic, LLC, ATS Laboratories, Inc., Avee Laboratories Inc., eScreen, Inc., Global Analytical Development LLC, Ionian Technologies Inc., Pembroke Occupational Health, Inc., Screen Tox, Inc., and Standing Stone, Inc., as guarantors, the Company as issuer, the other guarantor subsidiaries named therein, as guarantors, and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.13 to Alere Informatics, Inc., Alere Wellogic, LLC, ATS Laboratories, Inc., Avee Laboratories Inc., eScreen, Inc., Global Analytical Development LLC, Ionian Technologies Inc., Pembroke Occupational Health, Inc., Screen Tox, Inc., and Standing Stone, Inc. s Registration Statement on Form 8-A, filed on April 3, 2013)

- 4.2 Fifteenth Supplemental Indenture to Indenture dated as of May 12, 2009 (to add the guarantees of Alere Informatics, Inc., Alere Wellogic, LLC, ATS Laboratories, Inc., Avee Laboratories Inc., eScreen, Inc., Global Analytical Development LLC, Ionian Technologies Inc., Pembroke Occupational Health, Inc., Screen Tox, Inc., and Standing



**Table of Contents**

<b>Exhibit No.</b>	<b>Description</b>
	Stone, Inc.) dated as of April 3, 2013 among Alere Informatics, Inc., Alere Wellogic, LLC, ATS Laboratories, Inc., Avee Laboratories Inc., eScreen, Inc., Global Analytical Development LLC, Ionian Technologies Inc., Pembroke Occupational Health, Inc., Screen Tox, Inc., and Standing Stone, Inc., as guarantors, the Company as issuer, the other guarantor subsidiaries named therein, as guarantors, and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2013)
4.3	Sixteenth Supplemental Indenture to Indenture dated as of August 11, 2009 (to add the guarantees of Alere Informatics, Inc., Alere Wellogic, LLC, ATS Laboratories, Inc., Avee Laboratories Inc., eScreen, Inc., Global Analytical Development LLC, Ionian Technologies Inc., Pembroke Occupational Health, Inc., Screen Tox, Inc., and Standing Stone, Inc.), dated as of April 3, 2013, by and among the Company, the subsidiary guarantors named therein and Bank of New York Mellon Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.6 of the Company's Registration Statement on Form S-4 (File No. 333-187776))
4.4	Sixteenth Supplemental Indenture, dated as of May 24, 2013 to Indenture dated as of May 12, 2009 by and among the Company, the subsidiary guarantors named therein and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K, event date May 23, 2013, filed May 30, 2013)
4.5	Form of 6.5% Senior Subordinated Notes due 2020 (included in Exhibit 4.4)
4.6	Registration Rights Agreement, dated as of May 24, 2013, by and among the Company, the guarantors named therein, and Goldman, Sachs & Co., Jefferies LLC and Credit Suisse Securities (USA) LLC, as representatives of the Initial Purchasers (incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K, event date May 23, 2013, filed May 30, 2013)
10.1	Purchase Agreement dated May 13, 2013 among Alere Inc., the subsidiary guarantors named therein and Goldman, Sachs & Co., Jefferies LLC and Credit Suisse Securities (USA) LLC, as Representatives of the Initial Purchasers (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, event date May 10, 2013, filed May 16, 2013)
*31.1	Certification by Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
*31.2	Certification by Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
*32.1	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
*101	Interactive Data Files regarding (a) our Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2013 and 2012, (b) our Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2013 and 2012, (c) our Consolidated Balance Sheets as of June 30, 2013 and December 31, 2012, (d) our Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2013 and 2012 and (e) the Notes to such Consolidated Financial Statements.

\* Filed herewith

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 8, 2013

ALERE INC.

/s/ David Teitel  
David Teitel  
Chief Financial Officer and an authorized officer